



US 20250262139A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2025/0262139 A1**
AGREZ (43) **Pub. Date:** **Aug. 21, 2025**

(54) **POLYPEPTIDES AND METHODS FOR
IMPROVING SKIN CONDITIONS**

(71) Applicant: **INTERK PEPTIDE
THERAPEUTICS LIMITED**, New
South Wales (AU)

(72) Inventor: **Michael Valentine AGREZ**, New
South Wales (AU)

(21) Appl. No.: **18/036,105**

(22) PCT Filed: **Nov. 10, 2021**

(86) PCT No.: **PCT/AU2021/051332**

§ 371 (c)(1),

(2) Date: **May 9, 2023**

(30) **Foreign Application Priority Data**

Nov. 10, 2020 (AU) 2020904094

Publication Classification

(51) **Int. Cl.**

A61K 8/64 (2006.01)
A61K 38/00 (2006.01)
A61P 17/02 (2006.01)
A61Q 17/04 (2006.01)
A61Q 19/08 (2006.01)
C07K 7/06 (2006.01)
C07K 7/08 (2006.01)

(52) **U.S. Cl.**

CPC *A61K 8/64* (2013.01); *A61P 17/02*
(2018.01); *A61Q 17/04* (2013.01); *A61Q
19/08* (2013.01); *C07K 7/06* (2013.01); *C07K
7/08* (2013.01); *A61K 38/00* (2013.01); *A61K
2800/522* (2013.01); *A61K 2800/782* (2013.01)

ABSTRACT

The present disclosure relates to polypeptides, compositions and methods for preventing and/or treating skin conditions including dermal aging and skin conditions associated with UV and/or high energy visible light exposure.

Specification includes a Sequence Listing.

Fig. 1




Fig. 2




Fig. 3A




Fig. 3B




Fig. 4




Fig. 5









Non UV Treatment	UV Treatment
Vehicle 	Vehicle 
IK34720 20 µg 	IK34720 20 µg 
IK34720 100 µg 	IK34720 100 µg 
IK34720 200 µg 	IK34720 200 µg 
1,25(OH)₂D₃ 	1,25(OH)₂D₃ 

Fig. 6




Fig. 7




Fig. 8A




Fig. 8B





Fig. 9

Fig. 10




Fig. 11




Fig. 12




Fig. 13A




Fig. 13B




Fig. 14A




Fig. 14B




Fig. 15A




Fig. 15B




Fig. 16




Fig. 17




Fig. 18




Fig. 19





Fig. 20

A



B




Fig. 21





Fig. 22

A



Representative images of Aquaporin 3 staining on keratinocytes.

Dapi = blue = nuclei; Aquaporin 3 = green

B




Fig. 23




Fig. 24




Fig. 25




Fig. 26





Fig. 27

Evolution of cutaneous hydration rate on treated by the products "K-3 CREAM 50g 0.1%w/w" and "Aqueous Cream APF Base Control"



POLYPEPTIDES AND METHODS FOR IMPROVING SKIN CONDITIONS

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS

[0001] This application is a U.S. National Stage Application under 35 U.S.C. § 371 of International Patent Application No. PCT/AU2021/051332 filed Nov. 10, 2021, which claims the benefit of priority of Australian Patent Application No. 2020904094, filed Nov. 10, 2020, both of which are incorporated by reference in their entireties. The International Application was published on May 19, 2022, as International Publication No. WO/2022/099364 A1.

SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing, which has been submitted via EFS-Web and is hereby incorporated herein by reference in its entirety. Said ASCII copy, created on Apr. 17, 2023, is named AS FILED-63995-Sequence Listing-11263/011820-USO, and is 3,168 bytes in size.

TECHNICAL FIELD

[0003] The present disclosure relates to polypeptides, compositions and methods for preventing and/or treating skin conditions including dermal aging and skin conditions associated with UV and/or high energy visible light exposure.

BACKGROUND OF INVENTION

[0004] The cellular and molecular mechanisms of skin aging, skin damage and skin wound healing are not fully understood.

[0005] Skin aging is associated with loss of elasticity, dryness, wrinkles and pigmentation. Ultraviolet (UV) irradiation to the skin and, in particular, exposure to UVB having a wavelength of 290 to 320 nm, is known to cause chronic skin damage that includes premature skin aging and induction of skin cancer. Skin cancer costs the Australian health system more than \$700 million each year and the estimated number of new skin cancer cases diagnosed in 2018 is over 138,000.

[0006] UVB irradiation has been shown to induce expression of cyclooxygenase-2 (COX-2) with up-regulation of COX-2 playing a functional role in UVB-mediated tumour promotion. Moreover, the cyclic AMP response element binding protein (CREB) is phosphorylated and activated upon UVB treatment and is responsible for UVB-induced COX-2 expression.

[0007] The repair of photo-damaged DNA requires large amounts of cellular energy to unwind and remodel its compact chromatin structure to enable access of repair enzymes to the damaged DNA. The main source of energy within a cell is adenosine triphosphate (ATP). Exposure of the skin to UV-radiation puts the skin in a state of energy stress and the production of ATP is reduced, in part due to oxidative damage which inhibits mitochondrial function. The reduction in ATP availability also reduces the efficacy of the immune system, leading to UV induced immunosuppression. In this energy-deprived state following UV exposure the number of effector and memory T cells activated by antigen exposure is low. The immune-suppressive effects of UVB have been recognised for a number of decades.

[0008] Ultraviolet exposure, primarily UVB exposure, also leads to increases in reactive oxygen species (ROS) which in turn damage cellular and extra-cellular components such as DNA. Absorption of UV photons drives electrons and energy transfer from cellular photosensitisers, such as porphyrins, bilirubin, melanin, and pterins, to oxygen molecules creating the radical singlet O₂ anion. Consequently, the singlet oxygen anion induces guanine moiety oxidation of DNA followed by structural rearrangement and the formation of 8-hydroxy-2-deoxyguanosine moieties (8-OHdG). 8-OHdG is one of the most important DNA adducts and is used as an indicator of oxidative DNA damage associated with cellular aging and carcinogenesis.

[0009] Furthermore UV-irradiation directly affects DNA when DNA absorbs photons from UVB radiation. This results in structural re-arrangement of nucleotides that then lead to defects in the DNA strand. Cyclobutane pyrimidine dimers (CPDs) and pyrimidine (6-4) pyrimidone (6-4 photoproducts, 6-4 PPs) are the major products of UVB-induced DNA damage. Moreover, UVB-induced DNA damage in the form of CPDs can induce mutations in cells (such as epidermal cells) leading to the development of cancer. Reduction of CPDs through application of DNA repair enzymes prevents the risk of UV-induced skin cancer and apoptotic sunburn cells.

[0010] Unlike UV-irradiation, the role of visible light has been less extensively investigated, even though studies have demonstrated that visible light can induce cellular dysfunction and cell death both in vitro and in vivo. Visible light is the region of light with 400-700 nm in the electromagnetic spectrum. Blue light is the portion of the electromagnetic spectrum in the visible region with wavelengths ranging from 400-500 nm. The blue region (400-500 nm) of the visible spectrum is likely to be particularly important because it has a relatively high energy, can penetrate tissue (s), and is associated with the occurrence of malignant melanoma in animal models. The wavelengths of blue light are close to UVA spectrum (315-400 nm) and the blue region of the visible spectrum is particularly important because it has a relatively high energy and longer wavelengths that can penetrate tissue deeper than UV light due to its longer wavelengths.

[0011] Human skin tissue repair is commonly known as wound healing, which is an intricate process where the skin (or another organ-tissue) repairs itself after injury. In normal skin, the epidermis (the outermost layer) and dermis (the inner or deeper layer) exist in a steady-state equilibrium, forming a protective barrier against the external environment. Once the protective barrier is broken or damaged, the process of wound healing is immediately set in motion and may be divided into three or four sequential phases that can overlap and are not mutually exclusive, the phases being: hemostasis, inflammation, proliferation and remodelling.

[0012] Within these phases, growth factors cause cell proliferation, thus leading to an integration of dynamic changes that involve soluble mediators, blood cells, the production of the extracellular matrix, and the proliferation of parenchymal cells.

[0013] Compromised patients often develop non-healing chronic wounds that have failed to proceed through a timely reparative process to produce anatomic and functional integrity within a period of 3 months. Such wounds present a substantial economic burden to healthcare systems along with significant reductions in quality of life for those

affected. The cost in the USA is estimated to be approximately US\$20 billion with a UK report suggesting that treatment and care of chronic wounds accounts for 3% of total healthcare expenditure in developed countries.

[0014] Agents that can assist with tissue repair and particularly human wound healing are therefore required.

[0015] Topical treatments for cosmetic purposes have become a burgeoning field during the past 20 years, especially with polypeptides sequences that have a cosmetic function such as anti-oxidant activity or inhibition of proteases which damage the skin's ECM. Of the numerous skincare products that have been developed, many are for merely improving the appearance of human skin and treating signs and symptoms of aging. Other related products act to protect the skin by providing a screen that blocks UV radiation.

[0016] There remains a need for topical compositions that can treat and/or prevent a range of skin conditions including skin photoaging, skin damage and to promote wound healing.

SUMMARY OF INVENTION

[0017] The present inventors have identified that the polypeptide RSKAKNPLYRRRRRRRRR, and the polypeptide regions RSKAKNPLY and RRRRRRRRR, and the corresponding dextro-reverso form of the polypeptides (i.e. ylpnkaksr etc.), can be used to prevent or treat a range of skin conditions.

[0018] Accordingly, the present invention provides an isolated or purified polypeptide comprising the amino acid sequence RSKAKNPLY (SEQ ID NO: 5), or the dextro-reverso form of the amino acid sequence (i.e. ylpnkaksr-SEQ ID NO: 7), or a polyarginine amino acid sequence region (e.g. RRRRRRRRR-SEQ ID NO: 6), or the dextro-reverso form of the amino acid sequence (i.e. rrrrrrrrrr-SEQ ID NO: 8).

[0019] In one embodiment, the present invention provides an isolated or purified polypeptide comprising the amino acid sequence RSKAKNPLY (SEQ ID NO: 5), or the dextro-reverso form of the amino acid sequence (i.e. ylpnkaksr-SEQ ID NO: 7), or a polyarginine amino acid sequence region (e.g. RRRRRRRRR-SEQ ID NO: 6), or the dextro-reverso form of the amino acid sequence (i.e. rrrrrrrrrr-SEQ ID NO: 8). In some embodiments, the polypeptides are isolated or purified.

[0020] In some embodiments the polyarginine amino acid sequence region is C-terminal of the amino acid sequence RSKAKNPLY (SEQ ID NO: 5) or is N-terminal of the dextro-reverso form of the amino acid sequence (i.e. ylpnkaksr-SEQ ID NO: 7).

[0021] The polyarginine amino acid sequence region can be any suitable length. However, in some embodiments the polyarginine amino acid sequence region consists of 2 to 20 arginine residues. In some embodiments, the polyarginine amino acid sequence region consists of 4 to 20 arginine residues. In some embodiments, the polyarginine amino acid sequence region consists of 5 to 15 arginine residues. In some embodiments, the polyarginine amino acid sequence region consists of 5 to 12 arginine residues. In some embodiments, the polyarginine amino acid sequence region consists of 5 to 10 arginine residues. In some embodiments, the polyarginine amino acid sequence region consists of 5 to 9 arginine residues. In some embodiments, the polyarginine amino acid sequence region consists of 6 to 9 arginine

residues. In some embodiments, the polyarginine amino acid sequence region consists of 7, 8 or 9 arginine residues. In some embodiments, the polyarginine amino acid sequence region consists of 9 arginine residues.

[0022] In some embodiments, the polyarginine amino acid sequence region comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 arginine residues. In some embodiments, the polyarginine amino acid sequence region comprises 9 arginine residues.

[0023] Modifications of the C-terminus of the polypeptide of the present invention can change the biological activity of the polypeptides, and more accurately reflect natural polypeptides which typically undergo post-translational modifications. Therefore, in some embodiments, the polypeptide is modified at the C-terminus, preferably amidated at the C-terminus. In some embodiments, the dextro-reverso form of the amino acid sequence is amidated at the C-terminus (i.e. ylpnkaksr-NH₂). In some embodiments, the polyarginine amino acid sequence region is amidated at the C-terminus.

[0024] Amino acids are chiral at the alpha carbon adjacent to the carboxyl group, and as such exist as L- and D-isomers. In some embodiments of the invention, the polypeptide comprises L amino acids. In some embodiments of the invention, the polypeptide comprises D amino acids.

[0025] As indicated above, the present inventors have identified that the polypeptides of the invention have biological activity, including reducing DNA damage. Importantly, RSKAKNPLYRRRRRRRRR comprises the polypeptides RSKAKNPLY (IK94000) and RRRRRRRRR (IK00900), which are demonstrated herein to behave in same the manner as the polypeptide RSKAKNPLYRRRRRRRR. For example. Example 11 shows that the polypeptides IK34720 (SEQ ID NO: 3; "IK"; "IK14800" RSKAKNPLYRRRRRRRR), RSKAKNPLY (SEQ ID NO: 5; IK94000) and RRRRRRRRR (SEQ ID NO: 6; IK00900), each reduce DNA damage in primary keratinocytes following exposure to UV-irradiation.

[0026] Accordingly, RSKAKNPLYRRRRRRRRR comprises the polypeptides RSKAKNPLY (IK94000) and RRRRRRRRR (IK00900), can each be used separately, or in combination, in the compositions, methods and uses described herein.

[0027] Accordingly, the present invention provides a polypeptide as described herein for promoting wound healing. In some embodiments, the polypeptide for promoting wound healing comprises (or consists of) RSKAKNPLY (SEQ ID NO: 5). In some embodiments, the polypeptide for promoting wound healing comprises (or consists of) ylpnkaksr (SEQ ID NO: 7).

[0028] Accordingly, the present invention provides a polypeptide as described herein for promoting wound healing. In some embodiments, the polypeptide for promoting wound healing comprises (or consists of) RRRRRRRRR (SEQ ID NO: 6).

[0029] As indicated above, the present inventors have identified that the polypeptides of the invention can treat and/or prevent a skin condition. Accordingly, the present invention provides a polypeptide as described herein for treating or preventing a skin condition. In some embodiments, the polypeptide for treating or preventing a skin condition comprises (or consists of) RSKAKNPLY (SEQ ID NO: 5). In some embodiments, the polypeptide for treating or preventing a skin condition comprises (or consists of)

ylnpkaksr (SEQ ID NO: 7). In some embodiments, the polypeptide for treating or preventing a skin condition comprises (or consists of) RRRRRRRRR (SEQ ID NO: 6). [0030] In some embodiments, the skin condition is any one or more of: skin aging; oxidative damage; damage induced by sunlight exposure; ultraviolet radiation induced damage; UVB induced damage; and/or DNA damage.

[0031] In some embodiments, one or more of the above skin conditions are characterised by CPD and/or 8-OHdG formation, preferably DNA damage characterised by CPD and/or 8-OHdG formation or ultraviolet induced damage characterised by CPD and/or 8-OHdG formation.

[0032] In some embodiments, the polypeptides of the present invention inhibits, in a cell or in the skin of a subject, any one or more of: CREB phosphorylation; 8-OHdG formation; cyclobutane pyrimidine dimer (CPD) formation; matrix metalloproteinase 1 (MMP1) activity; oxidative damage of cellular or extracellular components; and/or DNA damage.

[0033] In one embodiment, the skin damage is HEV light induced damage.

[0034] In some embodiments the polypeptides of the present invention increases, in a cell or in the skin of a subject, any one or more of: Adenosine triphosphate (ATP) levels; and/or ultraviolet radiation damage repair.

[0035] The polypeptide of the present invention is useful when formulated as a composition. Therefore, the present invention provides a composition for topical use comprising a polypeptide described herein and a topically-acceptable carrier. The present invention also provides a topical composition comprising a polypeptide described herein and a topically-acceptable carrier.

[0036] The composition of the present invention may comprise one or more further active agent, preferably for promoting wound healing and/or treating or preventing a skin condition. Moreover, the present invention provides a composition for cosmetic use comprising a polypeptide as described herein and a cosmetically acceptable carrier, excipient or diluent. Further, the present invention provides a cosmetic composition comprising a polypeptide as described herein and a cosmetically acceptable carrier, excipient or diluent. Additionally, the present invention provides a pharmaceutical composition comprising a polypeptide as described herein and a pharmaceutically acceptable carrier.

[0037] In some embodiments, the composition further comprises one or more lipids and/or one or more further active agents. The polypeptide as described herein has been identified as having antioxidant activities and therefore in some embodiments, the isolated or purified polypeptide protects the one or more lipids and/or the one or more further active agents from oxidative damage.

[0038] Further provided by the present invention is the use of a polypeptide as described herein for the manufacture of a topical composition, cosmetic composition, and/or pharmaceutical composition.

[0039] The present invention provides a method for promoting wound healing, or treating or preventing a skin condition in a subject (such as a mammal), comprising administering to the mammal, to the wound, or to a site of the skin condition an effective amount of a polypeptide comprising a polypeptide as described herein or a composition as described herein. Preferably the polypeptide or composition is administered to the skin of the subject. In

some embodiments of the method the invention may be one or more of: skin aging, oxidative damage; damage induced by sunlight exposure; ultraviolet radiation induced damage; UVB induced damage; UVA induced damage; and/or DNA damage.

[0040] In some embodiments of the method, the one or more of the above skin conditions are characterised by CPD and/or 8-OHdG formation, particularly DNA damage characterised by CPD and/or 8-OHdG formation or ultraviolet induced damage characterised by CPD and/or 8-OHdG formation. In another embodiment, the skin damage is HEV light induced damage. In a further embodiment, the skin damage is reduced expression of AQP-3.

[0041] The present invention also provides a method for inhibiting matrix metalloproteinase 1 (MMP1) activity in a cell, or in the skin of a subject, comprising treating the cell or the skin with a polypeptide or a composition as described herein.

[0042] Further provided is a method for inhibiting CREB phosphorylation in a cell, the method comprising treating the cell with a polypeptide or composition as described herein. Additionally, provided is a method for inhibiting 8-OHdG formation in a cell, comprising treating the cell with a polypeptide or composition as described herein. A method is further provided for inhibiting CPD formation in a cell, the method comprising treating the cell with a polypeptide or composition as described herein. A method is further provided for maintaining Aquaporin-3 (AQP3) expression and/or AQP3 activity in the skin of a subject, comprising treating the skin with an isolated or purified polypeptide or composition as described herein. A method is further provided for maintaining Aquaporin-3 (AQP3) expression and/or AQP3 activity in a cell, comprising treating the cell with an isolated or purified polypeptide or composition as described herein.

[0043] Further provided is a method of increasing hydration or moisturisation of the skin of a subject, comprising administering to the skin an isolated or purified polypeptide or composition as described herein.

BRIEF DESCRIPTION OF DRAWINGS

[0044] Certain embodiments are illustrated by the following Figures. It is to be understood that the following description is for the purpose of describing particular embodiments only and is not intended to be limiting with respect to the description.

[0045] FIG. 1 shows the effect of the polypeptide IK34720 (SEQ ID NO: 3-RSKAKNPLYRRRRRRRR) on wound healing.

[0046] FIG. 2 shows the effect of the polypeptide IK236770 (SEQ ID NO: 4-rrrrrrrrlylnpkaksr) on wound healing.

[0047] FIG. 3A shows the effect of the polypeptide IK34720 (SEQ ID NO: 3) on preventing UV-irradiation induced phosphorylation of Cyclic-AMP-responsive element-binding protein (CREB), and FIG. 3B shows the effect of the polypeptide IK34720 (SEQ ID NO: 3) on restoring UV-induced suppression of TGF β receptor II (TGF β RII).

[0048] FIG. 4 shows the effect of the polypeptide IK34720 (SEQ ID NO: 3) on ATP levels in primary keratinocytes exposed to solar simulated UV-irradiation.

[0049] FIG. 5 is immunohistology illustrating the effect of the polypeptide IK34720 (SEQ ID NO: 3) on inhibiting UV-induced oxidative stress in the skin.

[0050] FIG. 6 shows the effect of the polypeptide IK34720 (SEQ ID NO: 3) on inhibiting UV-induced oxidative stress in the skin.

[0051] FIG. 7 is immunohistology illustrating the effect of the polypeptide IK34720 (SEQ ID NO: 3) on UV-induced DNA damage, as demonstrated by formation of Cyclobutane pyrimidine dimers (CPDs) in vitro.

[0052] FIG. 8 shows the effect of the polypeptide IK34720 (SEQ ID NO: 3) on UV-induced DNA damage, as demonstrated by formation of CPDs in vitro.

[0053] FIG. 9 is immunohistology illustrating the effect of the polypeptide IK34720 (SEQ ID NO: 3) on UV-induced DNA damage, as demonstrated by formation of CPDs in vivo.

[0054] FIG. 10 shows the effect of the polypeptide IK34720 (SEQ ID NO: 3) on UV-induced DNA damage, as demonstrated by formation of CPDs in vivo in a murine model.

[0055] FIG. 11 illustrates the effects of the polypeptide IK34720 (SEQ ID NO: 3) on cell apoptosis following UV-irradiation.

[0056] FIG. 12 is immunohistology illustrating the effect of the polypeptide IK34720 (SEQ ID NO: 3) on UV-induced DNA damage, as demonstrated by formation of CPDs in human skin explants.

[0057] FIG. 13 shows the effect of the polypeptide IK34720 (SEQ ID NO: 3) on UV-induced DNA damage, as demonstrated by formation of CPDs in human explants.

[0058] FIG. 14 illustrates the effect of the polypeptide IK34720 (SEQ ID NO: 3) on the number of apoptotic cells in human skin explants 3 hrs after UV-irradiation.

[0059] FIG. 15 illustrates the effect of the polypeptide IK34720 (SEQ ID NO: 3) on the number of apoptotic cells in human skin explants 24 hrs after UV-irradiation.

[0060] FIG. 16 shows the effect of the polypeptide IK34720 (SEQ ID NO: 3) on MMP-1 activity.

[0061] FIG. 17 shows the effect of the polypeptide IK34720 (SEQ ID NO: 3) on the percentage of MMP-1 positive cells in human skin explants 3 hours after UV-irradiation.

[0062] FIG. 18 shows the effect of the polypeptide IK34720 (SEQ ID NO: 3) on the percentage of MMP-1 positive cells in human skin explants 3 hours after UV-irradiation.

[0063] FIG. 19 shows the effect of the polypeptide IK34720 (SEQ ID NO: 3) on Thiol Redox State (TRS) in primary fibroblast lysates.

[0064] FIG. 20 shows the effect of the polypeptide IK34720 (SEQ ID NO: 3) on the melanin content of (A) lightly pigmented melanoma cells and (B) human primary melanocytes.

[0065] FIG. 21 shows the effect of the polypeptides IK34720 (SEQ ID NO: 3; "IK"); RSKAKNPLY (SEQ ID NO: 5, "IK94000") and RRRRRRRRR (SEQ ID NO: 6; "IK00900") on UV-induced DNA damage, as demonstrated by formation of Cyclobutane pyrimidine dimers (CPDs) in vitro.

[0066] FIG. 22 shows the effect of the polypeptide IK34720 (SEQ ID NO: 3; "IK-3") on the expression of Aquaporin-3 on Normal Human Epidermal Keratinocytes (NHEK). A; representative images of Aquaporin 3 staining on keratinocytes. Dapi=blue=nuclei; Aquaporin 3=green. B; percent Aquaporin 3 positive cells+standard error of the mean.

[0067] FIG. 23 shows variations in cutaneous hydration rate following polypeptide IK34720 (SEQ ID NO: 3; "IK-3") cream application.

[0068] FIG. 24 shows the evolution of cutaneous hydration rate on treated (polypeptide IK34720 (SEQ ID NO: 3; "IK-3" cream) and non-treated zones.

[0069] FIG. 25 shows variations in cutaneous hydration rate following Aqueous Cream APF Base application.

[0070] FIG. 26 shows the evolution of cutaneous hydration rate on control treated (Aqueous Cream APF Base) and non-treated zones.

[0071] FIG. 27 the evolution of cutaneous hydration rate comparing polypeptide IK34720 (SEQ ID NO: 3; "IK-3") cream and Aqueous Cream APF Base.

DETAILED DESCRIPTION

[0072] The nucleotide and polypeptide sequences referred to herein are represented by a sequence identifier number (SEQ ID NO:). A summary of the sequence identifiers is provided in Table 1. A sequence listing is also provided as part of the specification.

TABLE 1

Table of Sequence Listings		
Sequence ID Number (SEQ ID)	length	Sequence
SEQ ID NO: 1	10	RSKAKNPLYR
SEQ ID NO: 2	10	rylpnkaksr
SEQ ID NO: 3	18	RSKAKNPLYRRRRRRRR
SEQ ID NO: 4	18	rrrrrrrrrrylpnkaksr
SEQ ID NO: 5	9	RSKAKNPLY
SEQ ID NO: 6	9	RRRRRRRRR
SEQ ID NO: 7	9	ylpnkaksr
SEQ ID NO: 8	9	rrrrrrrrr
SEQ ID NO: 9	10	rskaknplyr
SEQ ID NO: 10	18	rskaknplyrrrrrrrr
SEQ ID NO: 11	9	rskaknply

*lowercase indicates dextrorotatory (dextro) amino acids

[0073] As will be described in more detail below, the present inventors have demonstrated that a polypeptide comprising the amino acid sequences RSKAKNPLY (SEQ ID NO: 5), or the dextro-reverso form of the amino acid sequence (i.e. rylpnkaksr—SEQ ID NO: 2, ylpnkaksr—SEQ ID NO: 7), and/or a polyarginine amino acid sequence region (e.g. RRRRRRRR; SEQ ID NO: 6) or the dextro-reverso form of the amino acid sequence (SEQ ID NO: 8), can treat a range of skin conditions such as promoting wound healing, treating or preventing aging, and can also treat and/or prevent the effects of UV-induced skin changes and cellular damage.

[0074] As used herein, the terms "IK34720", "IK" or "IK-3" are used interchangeably to refer to SEQ ID NO: 3 (RSKAKNPLYRRRRRRRR).

[0075] As used herein, the term “IK236770” is used interchangeably to refer to SEQ ID NO: 4 (rrrrrrrrylpnkaksr).

[0076] As used herein, the term “IK00900” is used interchangeably to refer to SEQ ID NO: 6 (RRRRRRRRRR).

[0077] As used herein, the term “IK94000” is used interchangeably to refer to SEQ ID NO: 5 (RSKAKNPLY).

[0078] The term “skin” as used herein, refers to at least the epidermis and dermis. As such, when used in relation to a skin condition, skin damage or skin wound, the term should be construed as not excluding conditions, damage or wounds that encompass additional tissues (such as the subcutaneous tissue) in addition to the epidermis and dermis.

[0079] The term “polypeptides” as used in the present specification refers to molecules composed of amino acid monomers, typically linked by amide bonds. The term includes a ‘pro-drug’ of the polypeptides, charged and non-charged forms of the polypeptides, a pharmaceutically acceptable salt of the polypeptides, and any other variant, derivative or modification to the polypeptides, including modifications to the backbone and/or termini of the polypeptides, which retain functional activity in the methods and uses of the present disclosure.

[0080] Further, the term polypeptide, as used herein, should not be interpreted as implicitly specifying a maximum length of the number of amino acids that can form the molecule. However, in some embodiments, when specified, the maximum length of the polypeptides is 50 amino acids. In some embodiments, the maximum length is 45 amino acids. In some embodiments, the maximum length of the polypeptides is 40 amino acids. In some embodiments, the maximum length is 35 amino acids. In some embodiments, the maximum length is 30 amino acids. In some embodiments, the maximum length is 25 amino acids. In some embodiments, the maximum length is 20 amino acids. In some embodiments, the maximum length is 18 amino acids.

[0081] In some embodiments, the polypeptide is an isolated or purified polypeptide.

[0082] Methods of “isolation” and “purification” of a polypeptide produced by natural or recombinant techniques are known in the art, for example in C-H Lee, *A Simple Outline of Methods for Protein Isolation and Purification*, Endocrinology and Metabolism; 2017 March; 32 (1): 18. Further, the terms “isolated” or “purified” include synthesised and other artificially produced polypeptides. Methods for synthesising polypeptides are known in the art. Generally, polypeptides are chemically synthesized by the condensation reaction of the carboxyl group of one amino acid to the amino group of another. Chemical synthesis of polypeptides can be carried out using solution-phase techniques or solid-phase techniques. Synthetic techniques can allow for the production of polypeptides incorporating unnatural amino acid polypeptides, backbone modification and synthesis of D-isomers.

[0083] As used herein, the term polyarginine refers to a sequence of contiguous arginine amino acids. In some embodiments the polyarginine amino acid sequence or polyarginine amino acid sequence region consists of 2 to 20 arginine residues. In some embodiments, the polyarginine amino acid sequence region consists of 4 to 20 arginine residues. In some embodiments, the polyarginine amino acid sequence region consists of 5 to 15 arginine residues. In some embodiments, the polyarginine amino acid sequence region consists of 5 to 12 arginine residues. In some embodi-

ments, the polyarginine amino acid sequence region consists of 5 to 10 arginine residues. In some embodiments, the polyarginine amino acid sequence region consists of 5 to 9 arginine residues. In some embodiments, the polyarginine amino acid sequence region consists of 6 to 9 arginine residues. In some embodiments, the polyarginine amino acid sequence region consists of 7, 8, or 9 arginine residues. In some embodiments, the polyarginine amino acid sequence region consists of 9 arginine residues.

[0084] In one aspect, the polyarginine amino acid sequence is RRRRRRRRR (SEQ ID NO: 9).

[0085] In one aspect of the isolated or purified polypeptides described herein, the amino acid sequence RSKAKNPLY (SEQ ID NO: 5), or the dextro-reverso form of the amino acid sequence ylpnkaksr (SEQ ID NO: 7), is adjacent the polyarginine amino acid sequence region.

[0086] In another aspect of the isolated or purified polypeptides described herein, the isolated or purified polypeptide further comprises a linker region in between the amino acid sequence RSKAKNPLY (SEQ ID NO: 5), or the dextro-reverso form of the amino acid sequence (ylpnkaksr; SEQ ID NO: 7), and the polyarginine amino acid sequence region. Linkers, such as polypeptide linkers, are known in the field.

[0087] In some embodiments, a polyarginine amino acid sequence region is N-terminal and/or C-terminal of the amino acid sequence RSKAKNPLY (SEQ ID NO: 5), or the dextro-reverso form of the amino acid sequence (i.e. ylpnkaksr-SEQ ID NO: 7). For example, in some embodiments, a polyarginine amino acid sequence region is C-terminal of RSKAKNPLY (SEQ ID NO: 5). In some embodiments, the polyarginine amino acid sequence region is N-terminal of ylpnkaksr (SEQ ID NO: 7).

[0088] In some embodiments, the polypeptide comprises the amino acid sequence RSKAKNPLYRRRRRRRR (SEQ ID NO: 3). In some embodiments, the polypeptide consists of the amino acid sequence RSKAKNPLYRRRRRRRR (SEQ ID NO: 3).

[0089] In some embodiments, the polypeptide comprises the amino acid sequence RSKAKNPLY (SEQ ID NO: 5). In some embodiments, the polypeptide consists of the amino acid sequence RSKAKNPLY (SEQ ID NO: 5).

[0090] In some embodiments, the polypeptide comprises the amino acid sequence ylpnkaksr (SEQ ID NO: 7). In some embodiments, the polypeptide consists of the amino acid sequence ylpnkaksr (SEQ ID NO: 7).

[0091] In some embodiments, the polypeptide comprises the amino acid sequence RRRRRRRRR (SEQ ID NO: 6). In some embodiments, the polypeptide consists of the amino acid sequence RRRRRRRRR (SEQ ID NO: 6).

[0092] In some embodiments, the polypeptides of the invention are modified. In some embodiments, the modification may be a modification that alters the pharmacological properties of the polypeptides. In some embodiments, the modification increases the half-life of the composition or polypeptides of the invention. In some embodiments, the modification may increase the bioactivity of the polypeptides (and/or the composition of the invention). In some embodiments, the modification may be a modification that increases selectivity of the polypeptides or compositions of the invention.

[0093] In one embodiment, the modification is the addition of a protecting group. The protecting group may be an N-terminal protecting group, a C-terminal protecting group

or a side-chain protecting group. The polypeptides of the present invention may have one or more of these protecting groups. The person skilled in the art is aware of suitable techniques to react amino acids with these protecting groups. These groups can be added by preparation methods known in the art. The groups may remain on the polypeptides or may be removed prior to use or administration. The protecting group may be added during synthesis.

[0094] In some embodiments, the polypeptide is amidated at its C-terminus. Amidation refers to the process of N-oxidative cleavage of glycine-extended substrates by sequential endo- and exoproteolysis. Methods are known in the art for producing amidated polypeptides in vitro, such as: enzymatic amidation; chemical modification of the C-terminus of recombinantly produced polypeptides and proteins; use of amide resins in solid-phase polypeptides synthesis; use of carboxypeptidase in the presence of ammonia; and conversion of the C-terminus of polypeptides to the methyl ester and addition of ammonia at low temperature. Examples of the disclosure of suitable techniques include DJ Merkler, C-terminal amidated polypeptides: production by the in vitro enzymatic amidation of glycine-extended polypeptides and the importance of the amide to bioactivity, Enzyme Microbial technology, 1994 June; 16 (6): 450-6 and V Čerovský and M-R Kula *C-Terminal polypeptides Amidation Catalyzed by Orange Flavedo polypeptides Amidase*; Angewandte Chemie, 1998 August; 37 (13-14): 1885.

[0095] Amidation of the C-terminus results in the C-terminal end being uncharged, so the modified polypeptides more closely mimic a native protein. This can have a series of advantages including an enhanced ability of the polypeptide to enter a cell; an improvement in the metabolic stability of the polypeptide in vivo; a decrease in the in vivo enzymatic degradation of the polypeptides by aminopeptidases, exopeptidases, and synthetases; and an improvement of the shelf-life of the polypeptides.

[0096] As is known in the art, alpha amino acids include a chiral carbon at the alpha position. Consequently, all alpha amino acids, with the exclusion of glycine, can exist in either of two enantiomers, being the L- or D-isomers. Generally, only L-amino acids are manufactured in mammalian cells and incorporated into proteins. D-amino acids can be artificially synthesised or may be found in bacterial proteins. The L and D convention is not used to directly refer to the stereochemistry of the amino acids, but rather to the optical activity of the isomer of glyceraldehyde from which that amino acid can be synthesized (D-glyceraldehyde is dextro-rotatory; L-glyceraldehyde is levorotatory).

[0097] In some embodiments, the polypeptide of the present invention comprises L-amino acids. In some embodiments the polypeptide of the present invention comprises only L-amino acids. In some embodiments the polypeptide of the present invention comprises D-amino acids. In some embodiments the polypeptide of the present invention comprises only D-amino acids. In some embodiments the polypeptide of the present invention comprises L-amino acids and D-amino acids.

Compositions

[0098] To facilitate application of the polypeptides, the polypeptides can be formulated into a composition. As defined herein a composition includes any admixture of components together with the polypeptides. In some forms, the composition is composed to stabilise the polypeptides

and/or protect the polypeptides and/or improve the application of the polypeptides. In some embodiments, the polypeptides can help stabilise another component of the composition, and/or protect another component of the composition, and/or improve the application of another component of composition.

[0099] Many compositions contain biological components, such as lipids, enzymes, proteins, polypeptides, elastin, collagen and fibrin. Further, compositions generally include an aqueous solvent. Biological components, in the presence of water, will typically be oxidised over time as a result of the hydrolytic activity of the water. This leads to degradation of the biological components and diminishes their function within the composition. Therefore, it may be advantageous to include additional components in the composition which can reduce oxidation of these biological components, such as a polypeptide of the present invention.

[0100] The problem is particularly exacerbated in an oil-in-water carrier, most commonly used in skin-care compositions. There is significant diffusion of oxygen at the water-oil interface in these compositions, which can result in serious degradation of biologically-active components, especially sensitive compounds encapsulated in the oil phase.

[0101] Accordingly, there is provided a composition containing the polypeptides of the present invention. In some embodiments, the composition contains a polypeptide of the present invention and at least one biological, or oxidisable, component. In some embodiments, the biological or oxidisable component is selected from the group consisting of: a lipid, an enzyme, a protein, a polypeptide, elastin, collagen and fibrin. In some embodiments, the composition comprises one or more lipids or one or more further active compounds. In some embodiments of the composition, the polypeptide in accordance with the present invention protects one or more lipids and/or one or more further active agents, or components, from oxidative damage.

[0102] A composition can be any suitable composition, and will be adapted for its particular use by a person skilled in the art. For example, the composition may be formulated for use in in vitro experiments or in vivo administration. In some preferred embodiments, the composition is a topical composition. In some embodiments, the composition is a pharmaceutical composition, preferably a topical pharmaceutical composition. In some embodiments the composition is a cosmetic composition, preferably a topical cosmetic composition.

Topical Composition

[0103] Importantly, the present inventors have demonstrated that the polypeptides are active when applied topically. For example, the present inventors have demonstrated that polypeptides described herein are able to promote wound healing, and decrease skin damage, when applied topically to skin in vivo or ex vivo. Accordingly, in one aspect, the present invention provides a composition for topical use, or a topical composition, comprising a polypeptide in accordance with the present invention and a topically acceptable carrier, diluent or excipient. In another aspect the present invention provides the use of a polypeptide in accordance with the present invention for the manufacture of a composition for topical use, or a topical composition. Preferably the composition for topical use is used for treating skin conditions, such as those described herein.

[0104] The term “topical composition” or “composition for topical use” refers to a composition that is formulated for topical administration, being the application primarily to keratinous tissue, primarily the skin, but may include hair and nails. Topical generally relates to delivery to the skin, but can also mean delivery to lumen spaces lined with epithelial cells, for example mucosal tissue such as the lips, mouth etc.

[0105] Formulations for topical delivery are described in D Osborne and A Aman (eds), 1990, *Topical drug delivery formulations*, CRC press Taylor & Francis and D Bhowmik et al. (2012) *Recent Advances In Novel Topical Drug Delivery System*, the Pharma innovation, 1:9, 12-31. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Tarun Garg, Goutam Rath & Amit K. Goyal (2015) *Comprehensive review on additives of topical dosage forms for drug delivery*, Drug Delivery, 22:8, 969-987.

[0106] A suitable form for topical administration comprises liquid, ointment, cream, gel, hydrogel, pomade, liniment, lotion, emulsion, spray, aerosol, drops or powder. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or colouring agents.

[0107] Drops or liquid sprays may be formulated with the polypeptides of the invention in an aqueous, or non-aqueous, base also comprising one or more of: dispersing agents, solubilizing agents or suspending agents. Drops can be delivered via a simple eye dropper-capped bottle, via a plastic bottle adapted to deliver liquid contents drop-wise, or via a specially shaped closure. Liquid sprays can be pumped or are conveniently delivered from pressurized aerosols and can be delivered via a targeted spray opening such as a manipulable tube or can be delivered via a spray aperture which spreads the liquid over a uniform area. Further, a solubilised form of the polypeptide can be contained in an absorbent medium which can then be placed or rubbed on the skin (for example a fabric wipe containing solubilised polypeptide).

[0108] In some forms of the invention, the polypeptides of the invention can be delivered via patches, plasters, poultices or bandages for dermal administration. Alternatively, the polypeptide can be formulated to be part of an adhesive polymer, such as polyacrylate or acrylate/vinyl acetate copolymer.

[0109] The topical composition may optionally comprise ingredients such as water, oils, salts, fragrances, perfumes, colorants, stabilisers, emulsifiers, propellants, additives, preservatives or preserving agents, anti-oxidants, surfactants, thickeners and other excipients normally used in topical compositions.

[0110] In some embodiments, the composition for topical use or the topical composition, comprises one or more further active agents for promoting wound healing, or treating or preventing a skin condition.

[0111] The term “treatment” and related terms as used herein refer to obtaining a desired pharmacologic and/or physiologic effect that is therapeutic in nature. For example, the effect may be therapeutic in terms of improving the condition of the subject, ameliorating, relieving and/or slow-

ing the progression of one or more symptoms in the subject, a partial or complete stabilization of the subject, or a cure in the subject.

[0112] The term “preventing” and related terms as used herein refer to obtaining a desired pharmacologic and/or physiologic effect that is prophylactic in nature. For example, the effect may be a complete or partial prevention of a disease, condition, state or symptom in the subject, or the complete or partial prevention of the progression or occurrence of symptoms or pathology in the subject.

[0113] Topical compositions in accordance with the present invention can be divided into cosmetic composition (or compositions intended solely for cosmetic uses), and pharmaceutical compositions (or compositions which are intended to be used, inter alia, for the prevention or treatment of a disease, ailment or condition).

Cosmetic Composition

[0114] The term “cosmetic composition” when used herein relates to a composition that can be used for cosmetic purposes, personal care and/or hygiene purposes. It will be appreciated that the composition may have more than one cosmetic purpose and may be used for more than one of these purposes at the same time. The term “cosmetic composition” when used herein can include but is not limited to, moisturising creams, facial and body powder and the like. Further, cosmetic compositions may include nail polish, compacts, solids, pencils, lipstick, mascara, rouge, foundation, blush, eyeliner or the like.

[0115] The US Food and Drug Administration (FDA) considers a cosmetic composition is defined by The Federal Food, Drug, and Cosmetic Act (FD&C Act), which defines cosmetics by their intended use, as “articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body . . . for cleansing, beautifying, promoting attractiveness, or altering the appearance” [FD&C Act, sec. 201 (i)]. Among the products included in this definition are skin moisturizers, perfumes, lipsticks, fingernail polishes, eye and facial makeup preparations, cleansing shampoos, permanent waves, hair colours, and deodorants, as well as any substance intended for use as a component of a cosmetic product.

[0116] Some products may be considered as both cosmetics and pharmaceutical, depending on their intended use. In such situations, the term “cosmetic” should be taken to exclude the pharmaceutical or therapeutic application of the composition.

[0117] Acceptable carriers or diluents for cosmetic uses are known in the art, and are described, for example, in AO Barel, M Payne and HI Mailbach (Eds) (2014) *Handbook of Cosmetic Science and Technology*, 4th Edition, CRC Press Taylor & Francis Group, USA.

[0118] A reference to a “non-therapeutic”, or “cosmetic”, methods and compositions throughout this specification should be taken to exclude any potential therapeutic methods or applications which may otherwise be encompassed by the claim(s). In some embodiments, a reference to a “non-therapeutic” or “cosmetic” method composition may allow for the specific disclaiming of a method of treatment by therapy performed on a human, or a composition for therapeutic treatment of a human. It is to be understood that while the compositions and methods of the present application may be biologically active, such as reducing photoaging or reducing the secretion of proteases or other enzymes, these

are not to be considered a method of therapy, or compositions for therapy, as there is no therapeutic indication or associated disease state.

Pharmaceutical Composition

[0119] In one aspect, the present invention provides a composition for pharmaceutical use, or a pharmaceutical composition, comprising a polypeptide in accordance with the present invention and a pharmaceutically acceptable carrier or diluent. In another aspect the present invention provides the use of a polypeptide in accordance with the present invention for the manufacture of a medicament for topical use, or a pharmaceutical composition.

[0120] The US Food and Drug Administration (FDA) considers pharmaceuticals as defined by The Federal Food, Drug, and Cosmetic Act (FD&C Act), in part, by their intended use, as “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease” and “articles (other than food) intended to affect the structure or any function of the body of man or other animals” [FD&C Act, sec. 201(g)(1)].

[0121] The composition also includes a pharmaceutically acceptable carrier, excipient or diluent. The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings or, as the case may be, an animal without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[0122] Suitable carriers include, but are not limited to, substantially inert solid, semi-solid or liquid fillers, diluents, excipients, encapsulating materials or formulation auxiliary of any type. An example of a pharmaceutically acceptable carrier is physiological saline or phosphate-buffered saline (PBS). Other physiologically acceptable carriers and their formulations are known in the art. Some examples of materials which can also serve as pharmaceutically acceptable carriers or excipients include sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; detergents such as TWEEN 80; buffering agents such as magnesium hydroxide and aluminium hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer’s solution; ethyl alcohol; and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulphate and magnesium stearate, as well as colouring agents, releasing agents, coating agents, sweetening, flavouring and perfuming agents, preservatives and antioxidants, suspending agent(s) and solubilising agent(s) can also be present. Examples of suitable binders include starch, gelatin, natural sugars such as glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweeteners, natural and synthetic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose and polyethylene glycol. Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride

and the like. In one embodiment the present invention provides preservatives and/or stabilizers. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also used.

[0123] Acceptable carriers are further described in the art, for example, in A. R. Gennaro (ed) 2015, *Remington’s Pharmaceutical Sciences*, 14th Edition, Mack Publishing Co. The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice.

[0124] “Pharmaceutical compositions” refers to an admixture of the polypeptides of the present invention in combination with one or more pharmaceutically acceptable diluents, excipients or carriers. In some forms the components of the admixture form an interworking relationship wherein the functionality of the active ingredient(s) (such as the polypeptide of the invention) is enhanced. For example, the admixture may increase the bioavailability of the polypeptide by improving or prolonging contact with the site of action such as the epidermis, dermis or wound; by reducing evaporation of the pharmaceutical composition; by improving stability of the polypeptide; by preventing enzymatic degradation or oxidation of the polypeptide; and/or by interacting with the polypeptide to create a synergistic relationship whereby the interaction of elements when combined produce a total effect that is greater than the sum of the individual elements. Typically, this synergistic relationship is manifested in a greater biological effect than can be achieved by the sum of the two components administered alone.

[0125] The pharmaceutical compositions may be for human or animal usage in human and veterinary medicine. Examples of such suitable excipients for the various different forms of pharmaceutical compositions described herein may be found in PJ Sheskey, W G Cook and CG Cable (eds) 2017, *Handbook of Pharmaceutical Excipients*, 8th Edition, APhA/Pharmaceutical Press, USA.

[0126] The term “effective amount” (for example a “therapeutically effective amount” or a “cosmetically effective amount”) as used herein refers to an amount that allows the achievement of the contemplated end, i.e. the healing of a wound, decrease in UV related damage and a decrease in photoaging. Said “effective amount” will vary from subject to subject, depending on the age and general condition of the individual and with the factors such as the particular condition being treated, the duration of the treatment, previous treatments and the nature and pre-existing duration of the condition (e.g. acute vs chronic wound).

[0127] Specifically, an effective amount of an agent defines an amount that can be administered to a subject without excessive or non-tolerable toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio, but one that is sufficient to provide the desired effect as assessed by an appropriate technique such as those disclosed throughout this specification. Thus, while it is not possible to specify an exact effective amount, those skilled in the art will be able to determine an appropriate “effective” amount in any individual case using routine experimentation and background general knowledge. A therapeutic result in this context includes eradication or lessening of symptoms. A therapeutic result need not be a complete amelioration of the condition (i.e. a cure).

[0128] The polypeptides of the invention may be administered, or formulated in a composition, in the form of a pharmaceutically acceptable salt. The pharmaceutically acceptable salts of the present invention can be derived from the parent polypeptide which contains a basic, acidic or metallic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting acidic or basic forms of the polypeptide with a stoichiometric amount of an appropriate counter base or acid in an aqueous or organic solvent. Generally, nonaqueous solvents such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Examples of acid addition salts include organic acids such as acetic, lactic, palmoic, maleic, citric, palmitic, salicylic, tartaric, malic, ascorbic, succinic, benzoic, suberic, methanesulfonic, toluenesulfonic, or trifluoroacetic acids or the like; polymeric acids such as tannic acid, carboxymethyl cellulose, or the like; and inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid phosphoric acid, or the like. Metal complexes include zinc, iron, and the like. Other pharmaceutically acceptable salts are contemplated. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., US, 1985, p. 1418, and Stahl et al, Eds, "Handbook of Pharmaceutical Salts Properties Selection and Use", Verlag Helvetica Chimica Acta and Wiley-VCH, 2002.

Skin Conditions

[0129] As discussed above, the present inventors have demonstrated that the polypeptides and compositions of the present invention are useful in treating skin conditions. Particularly, the polypeptides and compositions are useful in preventing or treating skin conditions associated with damage to the skin, generally as a result of an insult to the skin. Particularly exemplified skin conditions include wound healing, treating or preventing UV damage to the skin, preventing HEV light damage to the skin, treating or preventing skin aging including photoaging, treating or preventing oxidative stress and reactive oxygen species in skin cells, treating or preventing damage to the extracellular matrix (ECM) of the skin and treating or preventing DNA damage to cells of the skin.

[0130] For example, Example 1 demonstrates that the polypeptides IK34720 (SEQ ID NO: 3—RSKAKN-PLYRRRRRRRR) and the dextro-reverso sequence IK236770 (SEQ ID NO: 4—rrrrrrrylpnkaksr) promotes wound healing when applied topically, compared to untreated controls. Example 2 demonstrates that the polypeptide IK34720 (SEQ ID NO: 3) inhibits UV-induced phosphorylation of serine at position 133 of CREB (CREB S-133) in primary keratinocytes when applied following keratinocyte exposure to solar simulated UV-irradiation. Example 2 also shows that UV treatment suppresses TGF β RII levels, and the polypeptide IK34720 (SEQ ID NO: 3) restored TGF β RII expression in UV treated cells. The present inventors have also demonstrated that UV treatment suppresses Smad4 levels, and the polypeptide IK34720 (SEQ ID NO: 3) restored Smad4 expression in UV treated cells (data not shown); a downstream target of TGF β RII induced procollagen synthesis is Smad4. Example 3 demonstrates the polypeptide IK34720 ("IK", SEQ ID NO: 3) enhanced ATP levels in primary keratinocytes following exposure to solar simulated UV, to a similar level as Calcitriol. Example 4 demonstrates the polypeptide RSKAKN-

PLYRRRRRRRRR, when applied topically to skin following UV-irradiation, decreases oxidative stress in skin cells induced by UV-irradiation. Example 5 demonstrates the polypeptide RSKAKNPLYRRRRRRRR, when applied topically to skin following UV-irradiation, decreases DNA damage, as measured by the formation of CPD nuclei in skin cells induced by UV-irradiation. Example 6 demonstrates topical application of the polypeptide IK34720 (SEQ ID NO: 3) reduced the number of apoptotic keratinocytes following UV-irradiation. Example 7 demonstrates the polypeptide RSKAKNPLYRRRRRRRR, when applied topically to skin following UV-irradiation, can reduce the formation of CPD in human skin explants following acute UV-irradiation at 3 hours post irradiation. Example 8 demonstrates the polypeptide IK34720 (SEQ ID NO: 3) inhibits MMP-1 activation in a dose dependent manner, and when applied topically to skin following UV-irradiation, decreases MMP1 expression induced by UV-irradiation, indicating the polypeptide IK34720 (SEQ ID NO: 3) can be used to reduce photoaging over time. Example 9 demonstrates the polypeptide RSKAKNPLYRRRRRRRR, decreases UV-induced oxidative damage of cell-derived lipids in dermal skin fibroblast cell lysates. Example 10 demonstrates the polypeptide RSKAKNPLYRRRRRRRR, decreases melanin induction by UVB in lightly pigmented melanoma cells and human primary melanocytes. Example 11 demonstrates the polypeptides RSKAKNPLY (IK94000) and RRRRRRRRR (IK00900), which form part of the polypeptide RSKAKN-PLYRRRRRRRR, each reduce DNA damage in primary keratinocytes following exposure to UV-irradiation, and therefore act in the same manner as IK34720 (SEQ ID NO: 3; "IK"; "IK14800"). Example 12 demonstrates the polypeptide RSKAKNPLYRRRRRRRR reverses HEV light induced damage to human keratinocytes in primary keratinocytes following exposure to UV-irradiation. In particular, the polypeptide RSKAKNPLYRRRRRRRR reverses HEV light induced reduction in AQP3 levels in human keratinocytes. Compared to UVB-induced hyperpigmentation, HEV/blue light induces a more pronounced pigmentation that lasts up to 3 months. Visible light-induction of melanogenesis requires multiple exposures to visible light and results in darker and sustained pigmentation. Example 13 demonstrates the polypeptides RSKAKN-PLYRRRRRRRR (SEQ ID NO: 3), RSKAKNPLY (SEQ ID NO: 5), and RRRRRRRRR (SEQ ID NO: 6) reduce DNA damage in primary keratinocytes following exposure to UV-irradiation.

[0131] Accordingly, the present invention provides a method for treating a skin condition comprising administering to the skin, or cells of the skin, an effective amount of a polypeptide or composition as described herein.

[0132] As used herein, the terms "administering" or "providing" include administering the polypeptides, or administering a prodrug, or a derivative of the polypeptides, or a composition containing any one of the aforementioned polypeptides, that will result in the delivery of an effective amount of the active polypeptides within the body of the subject, or within the target cell.

Wound Healing

[0133] As discussed above, the present inventors have demonstrated that the polypeptides of the present invention are useful in promoting the healing of wounds. Accordingly, in an aspect of the present invention, there is provided a

polypeptide according to the present invention for promoting wound healing. In another aspect of the present invention there is provided a method for promoting wound healing in a mammal, comprising administering to the mammal an effective amount of a polypeptide or a composition in accordance with the present invention.

[0134] In this specification, the term "wound healing" is used to describe all the different steps involved in the healing of wounds and includes the augmentation and acceleration of the healing of the wound. It therefore includes the steps of forming a clot that plugs the defect, invasion of the clot by inflammatory cells and then of fibroblasts and capillaries to form a contractile granulation tissue that draws the wound margins together, and migration forward of the cut epidermal edges to cover the denuded wound surface.

[0135] The term "wound" as used herein refers to any wound to the tissue of the body. In a preferred form the term "wound" relates to dermal wounds where the skin is disrupted forming a tear, cut, puncture, incision, laceration, abrasion, rip, slash, scratch, slit, burn, rupture or ulceration in the skin of an animal.

[0136] Such wounds can be categorised as acute or chronic. Chronic wounds are defined as wounds that have failed to repair in a timely and orderly process of repair for at least a period of 3 months. Chronic wounds can be identified by the presence of a raised, hyperproliferative but non-advancing wound margin. Fibroblasts derived from the wound bed of chronic wounds of various aetiologies represent a senescent, premature, or differentiated phenotype, which do not respond or respond inefficiently to normal stimulatory messages.

[0137] All wound types have the potential to become chronic. Chronic wounds are traditionally divided etiologically, which may inform the treatment of the chronic wound. Further, treatment of the chronic wounds may also be accompanied by treatment of the underlying condition which may have instigated, or contributed to the formation of, the wound such as venous insufficiency, arterial perfusion, diabetes, unrelieved pressure as well as systemic factors such as nutritional status (Type I or Type II diabetes), immunosuppression and infection.

[0138] Common chronic wounds are venous ulcers, which usually occur in the legs and mostly affect the elderly, diabetic ulcers which are another major cause of chronic wounds, pressure ulcers, which usually occur in people with conditions such as paralysis that inhibit movement of body parts that are commonly subjected to pressure such as the heels, shoulder blades and sacrum, corneal ulcers, most commonly caused by an infection with bacteria, viruses, fungi or amoebae. Other types of chronic wounds may be due to causes such as ischemia and radiation poisoning.

[0139] Acute wounds can be categorised as any wound that does not meet the classification of a chronic wound. As such, acute wounds can be defined as wounds less than 3 months since the instigation of the wound site, often showing signs of wound healing within the first 4 weeks since instigation.

[0140] Acute wounds may be classified into different types, according to the object that caused the wound. For example, incisions or incised wounds, lacerations, abrasions and grazes, burns, puncture or penetration wounds.

[0141] In various embodiments the polypeptides or compositions of the invention may be used with, or the methods of the invention may further comprise, an adjunct treatment.

The adjunct treatment may include a debridement treatment such as the use of papain or other debridement agents known in the art, applications of a moist wound bed, or management of microorganism loads via anti-biotics or antifungals.

[0142] There are various techniques known in the art for measuring wound healing. These include but are not limited to the following.

[0143] Ruler technique—The surface area of a wound can be approximated by multiplying the greatest length and perpendicular width measurements. This technique is limited by the non-uniform nature of the shape of most wounds and as such this technique does not accurately predict the area of wounds having irregular shapes, which are large or deep. An alteration of this technique is to also measure the depth of the wound to predict the total wound volume. However, the accuracy of this technique is limited for the same reasons as discussed above.

[0144] Acetate Tracing and Planimetry—An alternative method for estimating wound area is acetate tracings and contact planimetry. This technique involves placing a transparent sheet across the wound surface and then tracing its margins. The area of the wound is then determined manually by placing the tracing over a grid and counting the number of squares within the circumscribed area, or by using computer image analysis to accurately quantify area.

[0145] Wound area estimation can also be estimated in non-contact manner such as non-contact planimetry. In this technique a target plate or scale gauge is placed in the same plane as the wound and an image is captured. Digital image analysis is undertaken to estimate the area of the wound with reference to the target plate/scale.

[0146] Three-dimensional estimation of wounds—More complicated three-dimensional topography measurement of wounds can be performed using structured light or laser light. These techniques, which are known in the art, use digital cameras and projected laser beams that distort with the curvature and depth of the wound surface.

Skin Damage and Skin Conditions

[0147] Importantly, the present inventors have further demonstrated that the polypeptides of the present invention can be used to prevent or treat damage caused to the skin by an insult to the skin (such as non-ionizing radiation damage, e.g. UV damage or HEV light damage) or by a medical condition of the skin. Accordingly, in an aspect, there is provided polypeptides according to the present invention for treating or preventing a skin condition. In another aspect, there is provided compositions for treating or preventing a skin condition. In another aspect, there is provided a method for treating or preventing a skin condition in a mammal, comprising administering to the mammal an effective amount of a polypeptide, or a composition as described herein.

[0148] Moreover, in another aspect there is provided a method for treating or preventing damage in a cell, the method comprising treating the cell with polypeptides as described herein.

[0149] In some embodiments, the skin condition is skin damage. In some embodiments, the damage is induced by sunlight exposure. In some embodiments, the skin condition is ultraviolet (UV) radiation induced damage. In some embodiments, the UV-radiation is UVB radiation, and the damage is UVB induced damage. In some embodiments, the UV-radiation is UVA radiation, and the damage is UVA

induced damage. In some embodiments, the skin condition is DNA damage. In some embodiments, the DNA damage is induced by UV-radiation, such as UVB or UVA radiation. In some embodiments the DNA damage is caused by UVB radiation. In some embodiments the DNA damage is caused by UVA radiation. In some embodiments, the damage is induced by HEV light exposure.

[0150] In some embodiments, the skin condition is oxidative damage. In some embodiments, the damage is increased cellular apoptosis. In some embodiments, the damage is damage to the extracellular matrix (ECM) of the skin. In some embodiments, the ECM is a collagen, elastin, laminin or a Proteoglycans, such as dermatan sulphate and hyaluronan.

[0151] In some embodiments, the polypeptides, compositions and methods(s) disclosed herein inhibit DNA damage. In some embodiments, the polypeptides, compositions and methods(s) disclosed herein increases repair of ultraviolet radiation induced damage and HEV-light induced radiation damage.

[0152] The term “treating” in the context of damage (such as damage caused by UV exposure or HEV light exposure) refers to reducing the relative level of any detrimental change caused in a cell, or tissue, as a result of the insult that caused the damage, when the polypeptides or compositions as described herein are applied, or the methods as described herein are performed, after the insult (e.g. UV-irradiation or HEV light exposure). Further, the term “prevention” in the context of damage refers to reducing the relative level of any detrimental change caused in a cell, or tissue, as a result of the insult that caused the damage, when the polypeptides or compositions as described herein are applied, or the methods as described herein are performed, before the insult, or before the induction of the detrimental change caused in a cell or a tissue as a result of the insult.

UV Damage

[0153] The present inventors have demonstrated that polypeptides in accordance with the present invention, such as the sequences RSKAKNPLYRRRRRRRR (SEQ ID NO: 3); RSKAKNPLY (SEQ ID NO: 5) and RRRRRRRRR (SEQ ID NO: 6), when applied topically to skin following UV-irradiation, reduce DNA damage.

[0154] Ultraviolet radiation is typically defined as electromagnetic radiation having a wavelength of 10 nm to 400 nm. The most common source of environmental UV-radiation is from the sun where it makes up 10% of total light output, with the most of it filtered out by the atmosphere of the earth such that at ground level about 3% of electromagnetic radiation from the sun is UV-radiation.

[0155] UV emitted from the sun primarily can be divided into UVA, UVB and UVC radiation. UVA is categorised as having a wavelength of 315 nm to 400 nm; UVB is categorised as having a wavelength of 280 nm to 315 nm; and UVC is categorised as having a wavelength of 100 nm to 280 nm. At sea level about 95% of UV-radiation is UVA, and about 5% being UVB with the UVC radiation being filtered out by the atmosphere.

[0156] It has been demonstrated in animal models and human skin explants that UVB and UVA induce photo-damage to the skin, with UVA penetrating deeper than UVB. UV-induced DNA photoproducts are able to cause specific mutations (UV-signature) in susceptible genes, and as such

are a causative agent in the induction of a range of skin cancers, including basal-cell carcinomas and melanomas.

[0157] As such, and as discussed above, the present invention provides polypeptides, compositions and methods for treating or preventing UV damage in the skin, in particular, in skin cells or in the ECM of the skin.

[0158] The types of damage caused by UV exposure are known in the art, and include (but are not limited to), DNA damage, apoptosis of cells, activation of intracellular signalling pathways by phosphorylation of cellular signalling molecules such as cAMP response element-binding protein (CREB) and generation of reactive oxygen species (ROS).

HEV Light Damage

[0159] High energy visible (HEV) light is high frequency light in the violet/blue band from 400 nm to 500 nm in the visible spectrum (400 nm-700 nm). The effect of HEV light on macular degeneration was studied and HEV light has been implicated as a cause in this age-related disorder. The mechanism by which HEV light damages the lens and the retina is believed to be an accumulation of reactive oxygen species (ROS) due to oxidative damage to cells and their organelles. These changes are irreversible.

[0160] Studies to evaluate the effect of HEV light on skin, show that the damaging effects to epidermal and dermal tissue are similar to the damaging effects on the eye. For example, one study showed that visible radiation (400-700 nm) of different wavelength ranges has different effects on the skin barrier recovery rate of hairless mice after barrier disruption. It was found that blue light (450-500 nm) delayed barrier recovery compared to a control kept in the dark. The barrier recovery was measured by means of transepidermal water loss (TEWL). Aquaporin 3 (AQP3) is known to be essential for maintenance of skin hydration. While one study proposed that Blue Light Induces Down-Regulation of Aquaporin 1, 3, and 9 in Human Keratinocytes (Cells, 2018, 7, 197) this study was subsequently retracted. Importantly, the present inventors have demonstrated that the polypeptide RSKAKNPLYRRRRRRRR reverses HEV induced reduction in AQP3 levels in human keratinocytes. Without wishing to be bound by theory, accordingly, the polypeptides described herein can be used to maintain AQP3 levels following HEV light exposure and skin hydration following HEV light exposure.

[0161] Denda et al. Journal of Investigative Dermatology (2008) 128, 1335-1336 demonstrated that HEV light exposed skin showed different morphology compared to control skin kept in the dark, with a depleted content of intercellular lipids between the stratum corneum (SC) and the stratum granulosum (SG) suggesting the prevention or suppression of processes that support barrier recovery.

[0162] High energy (HEV) light in the region of wavelengths between 400 nm and 500 nm contributes significantly to the production of free radicals in the skin. Free radical formation that has been detected following visible light exposure is significant, with UVB generating 4% of ROS, UVA generating 46%, and visible light generated 50% of ROS (O₂ and OH) production. Generation of these two highly reactive species can lead to a chain reaction and generation of other biological radicals, including secondary lipid radicals. CH-R in different skin layers. ROS production is well known to be involved in premature skin aging, often

accompanied by inflammatory cascades, generation of age spots and wrinkles, and in the promotion of cancerous skin lesions.

[0163] Importantly, HEV-light accelerates skin aging by an overexpression of damaging free radicals (at the deep live epidermis and dermis layers) and HEV light leads to a compromised skin barrier (at the stratum corneum and upper live epidermal layers). These two processes are known to be involved in skin aging. Overall, it has been suggested that HEV light causes as much skin damage as UVA and UVB radiation combined. As such, and as discussed above, the present invention provides polypeptides, compositions and methods for treating or preventing HEV damage in the skin, in particular, in skin cells or in the ECM of the skin.

[0164] As used herein, the term "HEV light" refers to light which is characterized as having wavelengths from 400 nm up to 500 nm. In one embodiment the HEV light is referred to as blue light.

[0165] In one embodiment, HEV light induced damages includes a reduction in AQP3 levels, skin ageing, decreased barrier function, delayed barrier recovery following HEV light exposure, decreased skin elasticity, decreased skin hydration, hyperpigmentation, and/or depleted content of intercellular lipids between the stratum corneum and the stratum granulosum.

[0166] As used herein, the term "maintains" includes maintaining AQP3 levels, preventing skin ageing, maintaining barrier function, maintaining barrier recovery following HEV light exposure, maintaining skin elasticity, maintaining skin hydration, and/or maintaining content of intercellular lipids between the stratum corneum and the stratum granulosum, and that a visual indicia of harm to the skin does not change over time, e.g., the incidence of wrinkles, sagging, skin tone, and/or that an indicia of harm to skin does not increase over time, but rather remains relatively constant.

Aquaporins

[0167] Aquaporins represent a group of structurally related proteins occurring in plant and animal cell membranes, which form channels (pores) for polar substances of low molar weight, in particular water.

[0168] Aquaporins render possible the quick exchange of larger amounts of water and glycerin through the plasma membrane and intracellular membranes, e.g., in erythrocytes, epithelial cells or growing plant cells.

[0169] In many organs, aquaporins play a critical role in the regulation of water content. They prevent cells, for example with a change of the salt concentration in the environment, from bursting (osmotic regulation). The primary secretion of urine and the secondary formation of urine in the kidney thus take place with the aid of aquaporins. The secretion formation of some exocrine glands (salivary gland, lacrimal gland) also involves aquaporins.

[0170] Aquaporins can be divided into two groups:

[0171] a) Pure water pores (aquaporins: AQP-0, 1, -2, -4, -5, -6 and -8) and

[0172] b) Pores that also allow small uncharged molecules, such as glycerin and urea, to pass in addition to water (aquaglyceroporines: AQP-3, -7, -9 and -10).

[0173] In mice deleted for AQP-3, the glycerin content of the skin is reduced and leads to a defective hydration of the stratum corneum, reduced skin elasticity and delayed barrier repair after damage to the stratum corneum. In the stratum corneum of the AQP-3 deleted mice, the water content is

reduced by a factor of three, which correlates with the reduced glycerin content (likewise a factor of three).

[0174] Dry skin in particular suffers from an insufficient water and glycerin content in the upper epidermis layers, thus also in the stratum corneum. Dry skin is often caused by exogenous factors, such as, e.g., stress conditions (UV radiation, winter climate, dry room atmosphere, e.g., through air conditioning) or through endogenic factors, such as, e.g., skin aging and atopy.

[0175] As discussed above and in the Examples, the present inventors have demonstrated that the polypeptide RSKAKNPLYRRRRRRRRR reverses HEV light induced reduction in AQP3 levels in human keratinocytes. Without wishing to be bound by theory, accordingly, the polypeptides described herein can be used to maintain AQP3 levels following HEV light exposure and skin hydration following HEV light exposure.

[0176] Accordingly, there is provided polypeptides and compositions(s) as described herein for maintaining AQP3 expression, restoring HEV-light induced suppression of AQP3 expression. Without wishing to be bound by theory, maintenance of aquaporin expression is expected to result in maintenance of the endogenous and exogenous supply of the skin with water and moisturizers, such as glycerin.

[0177] The present inventors have demonstrated in Example 14 that polypeptides and compositions(s) as described herein increase cutaneous hydration, for example at 24 hours following topical application.

[0178] In one aspect, disclosed herein are methods for enhancing hydration or moisturization of the skin of a subject (e.g., a human or animal), that comprise topically administering to the skin of the subject a composition comprising a polypeptide as described herein.

[0179] In some alternatives, the methods for enhancing hydration or moisturization of the skin described herein further comprise determining or measuring skin hydration or moisturization of the subject after administration of the composition comprising a polypeptide as described herein. One skilled in the art will readily appreciate that improvements in skin hydration or moisturization can be measured using known systems and techniques, including a number of methods and instruments that have been developed for studying skin physiology, biophysical properties, and function of the skin barrier. Generally, skin hydration or moisturization values can be determined by using any suitable techniques known in the art and can be determined by, for example, techniques developed for assessing skin hydration or moisturization based on one or more electrical properties of the skin such as measurement of resistance, alternating current conductivity (conductance), capacitance, and impedance of the skin surface as validated indicators of the hydration or moisture level of skin. For example, one skilled in the art will readily appreciate that skin hydration or moisturization can be determined by measuring electromagnetic radiation on the skin surface, or by determining change in the dielectric constant or dielectric permittivity due to variation in skin surface hydration or moisturization. Other non-limiting examples of suitable techniques for measuring skin hydration or moisturization in accordance with the methods described herein include determination of skin hydration or moisturization through measurements of thermal conductivity, or assessment of the skin hydration or moisturization value based on at least one elastographic parameter of the skin.

[0180] In one embodiment, determining or measuring skin hydration can be performed using a Corneometer® hydrometer.

DNA Damage and CPD Formation

[0181] There are a range of techniques known in the art for assessing DNA damage within a cell. These include (but are not limited to) the CometAssay®, PARP Universal Colorimetric Assay, Superoxide Dismutase Assay analysis of phosphorylated H2AX within cells, or production of cyclobutane pyrimidine dimers (CPDs).

[0182] During exposure of keratinocytes to UV-radiation, two forms of DNA damage are induced; cyclobutane pyrimidine dimers (CPDs), and pyrimidine photoproducts DNA damage. CPDs are highly mutagenic and are produced in substantial quantities by UV-radiation, particularly UVB radiation. These dimers can form between any two adjacent pyrimidines and can involve thymine, cytosine, or 5-methylcytosine. The mutagenicity of CPDs relates to their long persistence in skin cells. This allows time for deamination of the CPDs which, when the deaminated CPDs are bypassed by DNA polymerases, result in a mutagenic event.

[0183] The present inventors have demonstrated that polypeptides in accordance with the present invention, such as the sequence RSKAKNPLYRRRRRRRRR (SEQ ID NO: 3); RSKAKNPLY (SEQ ID NO: 5) and RRRRRRRRR (SEQ ID NO: 6), when applied topically to skin following UV-irradiation, decrease CPD formation. Therefore, in some embodiments there is provided polypeptides, compositions (s) and methods for reducing damage characterised by CPD formation in a cell, particularly UV-induced damage. Furthermore, in some embodiments there are provided polypeptides, compositions(s) and methods for preventing damage characterised by CPD formation in a cell, particularly UV-induced damage.

[0184] In some embodiments, the damage is CPD formation in a cell. Accordingly, in some embodiments, the polypeptides, the compositions and the methods described herein reduce CPD formation in a cell, particularly following UV exposure. Further, in some embodiments, the polypeptides, the compositions and the methods described herein prevent increases in CPD formation in a cell, particularly following UV exposure. Accordingly, there is provided a method for inhibiting CPD formation in a cell (such as a skin cell), comprising treating the cell with a polypeptide or composition in accordance with the present invention.

Oxidative Damage

[0185] Oxidative stress is the result of the imbalance between reactive oxygen species (ROS) formation and enzymatic and nonenzymatic antioxidants. A net imbalance can result in an accumulation of ROS within cells, and secreted from cells. The increase in ROS can cause a range of damage to cells and the extracellular matrix of a tissue (such as the skin) including DNA damage (for example double strand DNA breaks) and oxidative damage to both cellular and extracellular components, such as lipids and collagen. As discussed above, oxidative damage is caused by UV exposure and HEV light exposure.

[0186] The present inventors have demonstrated that polypeptides in accordance with the present invention, such as the sequence RSKAKNPLYRRRRRRRRR (SEQ ID NO: 3), when applied to UV irradiated skin, decreases oxidative

stress within a cell. In particular, the polypeptides in accordance with the present invention, such as the sequence RSKAKNPLYRRRRRRRRR (SEQ ID NO: 3), when applied topically to skin following UV-irradiation inhibits 8-OHdG formation in the skin.

[0187] Accordingly, the invention provides polypeptides and compositions as described herein for treating or preventing oxidative stress in a cell, or oxidative damage to the skin. In a further aspect, the invention provides a method for treating or preventing oxidative damage to the skin of a subject, comprising administering (preferably topically) to the subject an effective amount of a polypeptide or composition in accordance with the present invention. In some embodiments, the oxidative damage is UV-radiation induced oxidative damage, or HEV light induced oxidative damage. In some embodiments of the method, the polypeptides or composition is administered before UV-irradiation or HEV light exposure. In some embodiments of the method, the polypeptides or composition is administered after UV-irradiation or HEV light exposure.

[0188] The invention also provides polypeptides and compositions as described herein for treating and/or preventing an increase in ROS in a cell. In a further aspect, the invention provides a method for treating or preventing increases in ROS concentrations in the skin of a subject, comprising administering (preferably topically) to the subject an effective amount of a polypeptide or composition in accordance with the present invention. In some embodiments, the increase in ROS follows UV-irradiation or HEV-light exposure of the skin or cells. In some embodiments of the method, the polypeptides or composition is administered before UV-irradiation or HEV-light exposure. In some embodiments of the method, the polypeptides or composition is administered after UV-irradiation or HEV-light exposure.

[0189] Methods and techniques are known in the art to assess oxidative damage in a cell, for example I. Marrocco et al. Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans. *Oxidative Medicine and Cellular Longevity*, 2017, Article ID 6501046. These techniques include, but are not limited to: fluorescent probes for detection of ROS and ROS inducing nitrogen species (e.g. DHR123, DCFH-DA, HE and C11-BODIPY); markers based on ROS-induced modifications, such as lipid oxidation (e.g. HNE, F2-IsoPs, MDA, alkenals and alkadienals), oxidation of DNA (e.g. 8-OHdG, 5-chlorocytosine, 5-chlorouracil, EdA and adC) and oxidation of lipids (e.g. carbonils, 3-NO-Tyr, AOPPs, ALEs, AGEs and oxLDL).

[0190] As disclosed above, the present inventors have demonstrated that polypeptides in accordance with the present invention can reduce the concentration of 8-OHdG in a cell following UV exposure, and UV-induced damage. Therefore, the present invention provides polypeptides or compositions as described herein for reducing 8-OHdG in a cell. In some embodiments, the 8-OHdG is induced by UV-irradiation of the cell (ultraviolet stress). Further provided are methods for reducing 8-OHdG in a cell, comprising treating the cell with a polypeptide or composition as described herein. In some embodiments of the method, the polypeptides or composition is administered before UV-irradiation. In some embodiments of the method, the polypeptides or composition is administered after UV-irradiation. In some embodiments, the method inhibits or reduces

UVB induced damage, characterised by 8-OHdG formation. In some embodiments, the method inhibits or reduces UVA induced damage.

DNA Damage and Cellular Apoptosis

[0191] The present inventors have demonstrated that polypeptides in accordance with the present invention, such as the sequence RSKAKNPLYRRRRRRRR (SEQ ID NO: 3), when applied topically to skin, including human skin, following UV-irradiation reduced the number of apoptotic sunburn cells.

[0192] Damages caused to cells following an insult, such as UV-irradiation, can lead to cells undergoing programmed cell death via apoptosis. DNA damage caused by insults such as UV-irradiation and reactive oxygen species can regulate the function and activity of multiple apoptotic factors, such as p53, Ku70 and Ku86 (the Ku complex) and the MNR complex. This in turn can induce apoptosis in cells, with increased apoptosis being correlated with skin aging.

[0193] Accordingly, in one aspect the present invention provides polypeptides, compositions as described herein for reducing apoptosis in the skin (e.g. in one or more cells of the skin), or preventing apoptosis in a cell. In a further aspect, the invention provides a method reducing apoptosis in the skin, or preventing apoptosis in a cell, comprising administering (preferably topically) to the subject an effective amount of a polypeptide or composition in accordance with the present invention.

[0194] Methods are known in the art for assessing apoptosis in cells for example G Banfalvi, Methods to detect apoptotic cell death, *Apoptosis*, 2017 February; 22 (2): 306-323. These include, but are not limited to, analysis of: membrane alterations, DNA fragmentation, cytotoxicity and cell proliferation and mitochondrial damage. Further techniques include light-scattering flow cytometry, time-lapse microscopy perfusion assays and analysis of genotoxicity specific chromatin changes.

Cellular Energy and DNA Repair

[0195] The present inventors have demonstrated that polypeptides in accordance with the present invention, such as the sequence RSKAKNPLYRRRRRRRR (SEQ ID NO: 3), when applied topically to skin, including human skin, following UV-irradiation increases the levels of ATP in cells.

[0196] Vitamin D, which is produced in cells following UV-irradiation, is locally hydroxylated and protects cells against UV-induced damage. Further, the vitamin D steroid hormone 1alpha,25-dihydroxyvitamin D₃ (1,25 (OH)₂D₃; Calcitriol) has been shown to increase the protective effects of vitamin D and reduce DNA damage, and improve DNA repair, in a variety of models.

[0197] Moreover, it has recently been shown that 1,25 (OH)₂D₃ enhances glycolysis leading to energy-conserving processes. Critically, DNA repair is energy dependent and therefore an increase in intracellular energy, via increased Adenosine Triphosphate (ATP), can result in increased repair of CPDs and decreased oxidative damage. Therefore, the ability to increase the ATP concentration in a cell following UV-irradiation, should facilitate improved DNA repair.

[0198] Accordingly, in one aspect the present invention provides polypeptides and compositions as described herein

for increasing the ATP levels in a cell. In some embodiments, the increase in ATP in a cell is following UV exposure. Further provided is a method of increasing the ATP level in a cell, comprising treating the cell with polypeptides or compositions as described herein. In some embodiments, the cell is treated before exposure to UV-radiation. In some embodiments the cell is treated after exposure to UV-radiation.

CREB Activation

[0199] The present inventors have demonstrated that polypeptides in accordance with the present invention, such as the sequence RSKAKNPLYRRRRRRRR (SEQ ID NO: 3) inhibits formation of phosphorylated cAMP response element-binding protein (pCREB) in primary keratinocytes, when applied following keratinocyte exposure to solar simulated UV-irradiation.

[0200] CREB is a cellular transcription factor. It binds to certain DNA sequences called cAMP response elements (CRE), thereby increasing or decreasing the transcription of the genes and has a role in a range of cellular pathways including cell proliferation, cell cycle progression, metabolism, DNA repair, cell differentiation and cell survival. CREB activation is indicated by phosphorylated at the serine at position 133. Phosphorylation at position 133 is increased as a result of UV-irradiation and is considered as a marker and contributing agent of UV-induced damage to cells. As such, inhibition of CREB phosphorylation may decrease UV-induced damage to keratinocytes, and hence decrease UV damage to skin.

[0201] Accordingly, in one aspect, the present invention provides polypeptides and compositions in accordance with the present invention for reducing CREB phosphorylation. Further provided is a method for inhibiting CREB phosphorylation in a cell, comprising treating the cell with polypeptides or compositions in accordance with the present invention.

TGFbetaRII and Procollagen Synthesis

[0202] There are number of reports linking sunscreen protection with TGFB/Smad signalling and stimulation of procollagen synthesis (Rittie L & Fisher G J, *Ageing Res Reviews*, 2002, 1 (4): 705-720; Choi M S et al, *J Dermatol Sci*, 2007, 146 (2): 127-137; Bora N S et al, *Eur J Pharm Sci*, 2018, 127:261-275).

[0203] Moreover, it has also been reported that 8 hours post UV irradiation both TGFB2 and TGF β RII are reduced, and this parallels the reduced procollagen synthesis during the same time period raising the possibility that reduced procollagen synthesis is mediated, at least in part, by the observed alterations in the TGFB2-TGF β RII-Smad pathway (Quan T H et al, *J Invest Dermatol*, 2002, 119 (2): 499-506). Accordingly, solar ultraviolet irradiation reduces collagen in photo-aged human skin by down-regulating the TGF-beta type II receptor (Quan T et al, *Am J Pathol*, 2004, 165 (3): 741-51), and oxidative stress also impairs the TGF beta pathway via reduction of the TGFB type II receptor (He T et al, *Age (Dordr)*, 2014, doi: 10.1007/s11357-014-9623-6). Notably, in contrast to TGFB2, TGFB1 and TGFB3 expression increases upon UV exposure (Quan T H et al, *vide supra*). In turn, the loss of TGF-beta type II receptor prevents

downstream activation of Smad2/3 by TGF-beta, thereby, reducing expression of type I procollagen (He T et al, *vide supra*).

[0204] The present inventors have demonstrated that TGF β RII expression was clearly suppressed with UV irradiation and re-established with IK34720 (SEQ ID NO 3; IK) at 5 h post UV treatment in primary fibroblasts (FERA-TONIC-p5).

[0205] Accordingly, there is provided polypeptides and compositions(s) as described herein for increasing procollagen synthesis and/or restoring UV-induced suppression of TGF β RII.

Aging

[0206] Net skin aging is the result of two simultaneously occurring processes. The first, which can be referred to as "innate" or "intrinsic" aging affects the skin slowly inducing a partly-reversible degeneration of the connective tissues. The second process, which can be referred to as "extrinsic aging" or "photoaging" is mainly due to ultraviolet radiation which significantly contributes to a premature aging of the skin.

[0207] The independence of these two pathways is exemplified by animal models that demonstrate that even in the absence of exposure to UV-radiation, skin still ages over time. The process of dermal aging is complex and involves myriad intracellular changes, and changes to the ECM, which result in a loss of, inter alia, skin elasticity, tone and pigment. Two of the primary causes of skin aging are accumulated cellular damage and destruction of the ECM of the skin.

[0208] UV-irradiation induces damage to the epidermis and dermis, which can result in long-term effects like photoaging. Photoaged skin displays alterations in the cellular component and extracellular matrix with an increase in, and accumulation of, disorganized elastin and fibrillin in the dermis. Further, photoaging can result in a loss of interstitial collagens which are the major structural proteins of the dermal connective tissue.

[0209] As discussed above, HEV-light accelerates skin aging by an overexpression of damaging free radicals (at the deep live epidermis and dermis layers) and HEV light leads to a compromised skin barrier (at the stratum corneum and upper live epidermal layers). These two processes are known to be involved in skin aging. Overall, it has been suggested that HEV light causes as much skin damage as UVA and UVB radiation combined.

[0210] Accordingly, there is provided polypeptides and compositions as described herein for treating or preventing skin aging. The invention further provides a method for treating and/or preventing skin aging in a mammal, comprising administering (preferably topically) to the mammal an effective amount of a polypeptide or composition as described herein. In some embodiments, the aging is intrinsic aging. In some embodiments, the aging is extrinsic aging. In some embodiments, the extrinsic aging is photoaging.

[0211] The present invention provides polypeptides or compositions as described herein for inhibiting damage of cellular or extracellular components of the skin. In some embodiments, the damage is oxidative damage, such as damage caused by ROS (as discussed above), which can result in photoaging of the skin. In some embodiments, the damage is induced by UV-irradiation.

[0212] In some embodiments, the damage is enzymatic breakdown of the ECM. Accordingly, the present invention provides polypeptides and compositions as described herein for reducing degradation of the ECM and/or photoaging of the skin, in particular degradation following exposure of cells to UV-radiation and/or HEV light exposure. Further provided is a method for inhibiting degradation of the ECM and/or photoaging of the skin, comprising treating the skin, or a cell within the skin, with a polypeptide or composition as described herein.

[0213] As used herein, "skin aging" means the appearance of aging of the skin of a mammal. This includes both intrinsic aging and extrinsic aging, which is primarily caused by UV exposure and HEV light exposure of the skin. Therefore, "treating and/or preventing" aging or "anti-aging" refers to a slowing or inhibition in, and/or reversing of, the appearance of skin aging.

[0214] The underlying agents which induce these changes are reactive oxygen species (ROS), primarily UV- and HEV light-generated ROS. These ROS deplete and damage both non-enzymatic and enzymatic antioxidant defence systems of the skin. Consequently, in the presence of a depleted ROS defence system, antioxidants cause cellular damage primarily to cellular membranes, lipids and structural proteins such as elastin and collagens. Further underlying agents include Matrix metalloproteinases (MMPs).

MMPs

[0215] Matrix metalloproteinases (MMPs) are zinc-containing endopeptidases which are able to degrade various components of extracellular matrix (ECM) proteins, such as collagen, fibronectin, elastin, and proteoglycans. UV-irradiation has been shown to increase the expression and secretion of MMPs in skin, which via their degradation of ECM can contribute to photoaging.

[0216] The present inventors demonstrated that that polypeptides in accordance with the present invention, such as the sequence RSKAKNPLYRRRRRRRR (SEQ ID NO: 3), can reduce the activation of cellular matrix metalloproteinase 1 (MMP1).

[0217] Accordingly, the present invention provides polypeptides and compositions as described herein for reducing the concentration of MMPs following exposure of cells to UV-radiation. Further provided is a method for inhibiting MMP activity in a cell or tissue, comprising treating the cell or tissue (preferably topically) with a polypeptide or composition as described herein. In some embodiments, the MMP is MMP1.

[0218] By reducing the activity of MMPs in the skin, degradation of the skin's ECM, and photo-aging of the skin, can be reduced.

Measures of Aging

[0219] Signs of aging include, but are not limited to, spider veins on the nose, cheeks and neck; pigmented spots, such as freckles, solar lentigines (known as age or liver spots), and uneven skin colour; general loss of skin tone; increase in number of wrinkles; increase in depth of wrinkles; increase in length of wrinkles; increase in lines such as forehead frown lines; the presence of benign actinic keratosis. As such, the assessment of these dermal features can be used to assess aging.

[0220] Without wishing to be bound by theory, in some embodiments, the polypeptides and methods of the present invention could be used to prevent or reduce the formation of one of the signs of aging provided above. In some embodiments, the polypeptides, compositions and methods of the present invention prevent or reduce the formation of spider veins on the nose, cheeks and neck. In some embodiments, the polypeptides, compositions and methods of the present invention prevent or reduce the formation of pigmented spots. In some embodiments, the polypeptides, compositions and methods of the present invention prevent or reduce the formation of freckles. In some embodiments, the polypeptides, compositions and methods of the present invention prevent or reduce the formation of solar lentigines. In some embodiments, the polypeptides, compositions and methods of the present invention prevent or reduce the formation of uneven skin colour. In some embodiments, the polypeptides, compositions and methods of the present invention prevent or reduce the formation of general loss of skin tone. In some embodiments, the polypeptides, compositions and methods of the present invention prevent or reduce the number of wrinkles. In some embodiments, the polypeptides, compositions and methods of the present invention prevent an increase in, or reduce the depth of, wrinkles. In some embodiments, the polypeptides, compositions and methods of the present invention prevent or reduce an increase in the length of wrinkles. In some embodiments, the polypeptides, compositions and methods of the present invention prevent or reduce an increase in forehead frown lines. In some embodiments, the polypeptides, compositions and methods of the present invention prevent or reduce the formation of benign actinic keratosis.

[0221] Further, methods are known in the art for assessing skin aging for different skin-types. For example R Bazin, E Doublet. *Skin Aging Atlas. Volume 1. Caucasian Type.* Med'Com; 2007; R Bazin and F Flament 2010 *Skin Aging Atlas. Volume 2. Asian Type.* Editions Med'Com, France; R Bazin, F Flament and F Giron 2012 *Skin Aging Atlas. Volume 3. African-American Type.* Editions Med'Com, France; R Bazin, F Flament and V Rubert, 2015, *Skin Aging Atlas. Volume 4: Asian Type*, Editions Med'Com, France; R Bazin, F Flament and H Qiu, 2017, *Skin Aging Atlas. Volume 5: Photo-aging Face & Body* Editions Med'Com, France.

[0222] In one aspect the peptides described herein are administered separately, or in combination.

[0223] The present disclosure is further described by the following examples. It is to be understood that the following description is for the purpose of describing particular embodiments only, and is not intended to be limiting with respect to the above description.

EXAMPLE 1: The Polypeptides
RSKAKNPLYRRRRRRRRR and Rrrrrrrrylpnkaksr
Promote Wound Healing

[0224] FIGS. 1 and 2 illustrate the effect of polypeptides IK34720 (SEQ ID NO: 3—RSKAKNPLYRRRRRRRRR) (FIG. 1) and the dextro-reverso sequence IK236770 (SEQ ID NO: 4—rrrrrrrrylpnkaksr) (FIG. 2), on wound healing over 10 days in a murine wound model in accordance with the following protocol.

[0225] Three groups of 8 male ICR mice with a mean weight of 22 g (+2 g) were used in the present study. The animals were housed in individual cages during the study. Under isoflurane gas anaesthesia, the shoulder and back

region of each animal was shaved and a sharp punch (ID 12 mm) was used to induce a wound by removing the skin, including panniculus carnosus and adherent tissues on Day 1.

[0226] Following induction of the wound the polypeptides IK34720 and IK236770 were topically administered to the site of the wound at a dosage of 10 µg per animal. Further a positive control group was administered 10 µg per animal of an alpha 2A agonist (CGS-21680) which has been shown to improve wound healing (Montesinos M C et al, J. Exp. Med., 1997, 186:1615-1620). An additional group which comprised the administration of Phosphate buffered Saline (PBS) at pH 7.4 was used as a negative control.

[0227] The wound healing was analysed on Days 5, 7, 9 and 11 by tracing the periphery of the wound onto clear plastic sheets with the wound area calculated by an Image analyzer ProPlus (Media Cybernetics, Version 4.5.0.29. The percentage closure of the wound (%) was calculated. Percentage closure of the wound was determined on 5, 7, 9 and 11. ANOVA and Dunnett's test were applied to test significant significance between the treated groups (peptide and positive control groups) and the negative control group at each time point of measurement. Differences were considered statistically significant at P<0.05, and are indicated by *.

[0228] As shown in FIG. 1, topical application of 10 µg per mouse of IK34720 (SEQ ID NO: 3—RSKAKNPLYRRRRRRRRR) daily for 10 consecutive days was associated with a statistically significant increase (P<0.05) in wound closure percentage from Day 5 to Day 11. Further, and as expected, topical application of adenosine A2a agonist CGS-21680 (the positive control) at 10 µg/mouse was associated with an increase wound healing compared to the negative control, during the same study period.

[0229] As shown in FIG. 2, topical application of 10 µg per mouse of the polypeptide IK236770 (SEQ ID NO: 4) daily for 10 consecutive day was associated with a statistically significant increase in wound healing (as measured by wound closure % percentage) on day 5 compared with the negative control.

[0230] All values in FIGS. 1 and 2 represent mean+SEM at the designated time points.

[0231] This data illustrates that the polypeptides IK34720 (SEQ ID NO: 3—RSKAKNPLYRRRRRRRRR) and the dextro-reverso sequence IK236770 (SEQ ID NO: 4—rrrrrrrrylpnkaksr) promotes wound healing when applied topically, compared to untreated controls.

EXAMPLE 2: The Polypeptide
RSKAKNPLYRRRRRRRRR Inhibits pCREB
Formation in Primary Keratinocytes when Applied
Following Keratinocyte Exposure to Solar
Simulated UV-Irradiation, and Restores UV-Induced
Suppression of TGF β Receptor (TGF β RII)

[0232] CREB is phosphorylated at serine at position 133 (Ser-133) in response to cell exposure to UV-irradiation. Increases in CREB phosphorylation are associated with a range of functions including cell proliferation, cell cycle, metabolism, DNA repair, differentiation, inflammation, angiogenesis, immune responses and cell survival. Consequently, aberrant CREB phosphorylation is associated with tumour development, malignancy and survival (Steven. A and Seliger B., Oncotarget. 2016 Jun. 7; 7 (23): 35454-35465).

[0233] The influence of the polypeptide IK34720 (SEQ ID NO: 3) on CREB phosphorylation was assessed using the following protocol.

[0234] Keratinocytes were harvested and cultured as previously described (Gupta et al., J Invest Dermatol, 2007, 127 (3): 707-215). Keratinocytes, (passages 1-5) from 3 independent donors were used in the experiments illustrated in FIG. 3.

[0235] Positive control treatment (denoted “D” in FIG. 3) was prepared by solubilizing Calcitriol (1,25-dihydroxyvitamin D3 (1,25(OH)₂D₃)-Cayman Chemical, MI, USA) in 100% spectroscopic ethanol (Merck, Darmstadt, Germany) and the final concentration was determined by spectroscopy (NanoDrop 2000, Thermo Fisher Scientific, MA, USA). The polypeptide IK34720 (SEQ ID NO: 3) was solubilised in phosphate buffered saline (PBS) to a concentration of 1 mM at pH 7.2. A vehicle (denoted as “V” in FIG. 3) constituting 0.1% (v/v) spectroscopic ethanol and 0.1% (v/v) PBS was prepared for use as a negative control.

[0236] Cultured cells were irradiated by solar simulated UV-irradiation (ssUV) using an Oriel 1000W xenon-arc lamp (Stratford, CT, USA). Irradiation was administered at an energy level of 400 mJ/cm² for UVB and 3600 mJ/cm² for UVA (total 4000 mJ/cm²), measured by an OL754 radiometer (Optronics Laboratories Inc., Orlando, FL). This dosage equates to approximately 4 min irradiation of the sun at 12 noon in October in Sydney, Australia. Non-irradiated control cells, (SHAM), were simultaneously processed with irradiated cells but protected from ssUV. Irradiation solution was PBS containing 5 mM D-glucose. Keratinocytes were plated in 6-well plates.

[0237] Immediately following irradiation 1 nM of 1,25(OH)₂D₃, negative control (vehicle) or 0.1 µM, 1 µM and 5 µM of IK34720 (“IK” in FIG. 3, SEQ ID NO: 3) were added to the cell cultures. Cells were subsequently lysed and western blot (as previously described in Rybchyn et al., vide supra, 2017, Rybchyn et al., JBC, 2011; 286 (27): 23771-9) was used to analyse phosphorylation of ERK1/2-T202/Y204, GSK3α/β-S21/9, mTOR-S2448, CREB-S133 and α-tubulin (loading control). All antibodies used in the western blot were from Cell Signalling Technology (MA, USA).

[0238] FIG. 3A illustrates the effect of the polypeptide IK34720 (SEQ ID NO: 3) on preventing UV-irradiation induced phosphorylation of Cyclic-AMP-responsive element-binding protein (CREB). As can be seen from FIG. 3, the polypeptide IK34720 (SEQ ID NO: 3) inhibits UV-induced phosphorylation of serine at position 133 of CREB (CREB S-133) in primary keratinocytes when applied following keratinocyte exposure to solar simulated UV-irradiation.

[0239] Both intrinsic skin aging and UV-induced skin aging lead to a reduction of TGFβRII required for type 1 procollagen synthesis. Furthermore, stimulation of procollagen synthesis by sunscreen protection is linked to TGFβ signalling.

[0240] The influence of the polypeptide IK34720 (SEQ ID NO: 3) on TGFβRII phosphorylation was assessed using the following protocol.

[0241] Human skin dermal fibroblasts were cultured from keratome biopsies of healthy adult human skin. Cells were between passages three and six. For UV irradiation, sub-confluent cells were washed once with phosphate-buffered saline (PBS) and irradiated with UV. Immediately following irradiation, negative control (vehicle) or 1 µM, 2.5 µM, 5 µM

and 10 µM of IK34720 (“IK” in FIG. 3B, SEQ ID NO: 3) were added to the cell cultures.

[0242] For Western analysis, nuclear extracts were prepared, membrane fractions were prepared and resolved on 8% SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membrane, and reacted with primary antibodies. Blots were visualized and quantified.

[0243] FIG. 3B illustrates the effect of the polypeptide IK34720 (SEQ ID NO: 3) on restoring UV-induced suppression of TGFβ receptor (TGFβRII). As can be seen from FIG. 3B, UV treatment suppresses TGFβRII levels, and the polypeptide IK34720 (SEQ ID NO: 3) restored TGFβRII expression in UV treated cells. TGFβRII expression was clearly suppressed with UV irradiation and re-established with IK34720 (SEQ ID NO 3; IK) at 5 h post UV treatment in primary fibroblasts (FERATONIC-p5).

[0244] This indicates the polypeptide RSKAKN-PLYRRRRRRRRR, when applied following UV-irradiation, restores UV-induced suppression of TGFβRII.

**EXAMPLE 3: The Polypeptide
RSKAKNPLYRRRRRRRRR Increases ATP Levels
in Primary Keratinocytes Exposed to Solar
Simulated UV-Irradiation**

[0245] FIG. 4 illustrates the effect of the polypeptide IK34720 (SEQ ID NO: 3) on ATP levels in primary keratinocytes exposed to solar simulated UV-irradiation. Inadequately repaired DNA damage following UV exposure has been demonstrated to be a causative factor in skin cancer development. DNA repair requires energy, but after UV exposure skin cells have a limited capacity to produce ATP, which is the primary source of the energy.

[0246] The influence of the polypeptide IK34720 (SEQ ID NO: 3) on intracellular ATP following UV exposure was assessed using the following protocol.

[0247] Primary keratinocytes were harvested as described above in Example 2 and were either exposed to ssUV-irradiation (UVR), as described above in Example 2 or not irradiated (SHAM), in the presence or absence of Calcitriol (positive control) or polypeptide IK34720 (SEQ ID NO: 3; RSKAKNPLYRRRRRRRRR), at the concentrations described in Example 2. Calcitriol (1a,25-dihydroxyvitamin D3), has been demonstrated to reduce UV-induced DNA damage and photocarcinogenesis in a variety of models.

[0248] ATP levels were determined 1.5 hours after UVR using the CellTiter-Glo® 2.0 Assay (Promega, WI, USA) as described previously (Rybchyn et al., vide supra, 2017). All data in FIG. 4 is shown as mean+SD. *p<0.05, **p<0.01. Cells were prepared and irradiated as described above.

[0249] As can be seen from FIG. 4, the polypeptide IK34720 (“IK”, SEQ ID NO: 3) enhanced the ATP levels in primary keratinocytes following exposure to solar simulated UV, to a similar level as Calcitriol. Increases in ATP levels are proposed to assist in the repair of DNA following UV-induced damage.

[0250] This indicates the polypeptide RSKAKN-PLYRRRRRRRRR, when applied following UV-irradiation, increases ATP levels following exposure to solar simulated UV.

EXAMPLE 4: The Polypeptide RSKAKNPLYRRRRRRRRR, when Applied Topically to Skin Following UV-Irradiation, Decreases Oxidative Stress in the Skin

[0251] FIGS. 5 to 6 illustrate the effect of the polypeptide IK34720 (SEQ ID NO: 3) on inhibiting UV-induced oxidative stress in the skin.

[0252] 8-hydroxy-2'-deoxyguanosine or 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-OHdG/8-oxodG) is one of the predominant forms of free radical-induced oxidative lesions with the concentrations of 8-OHdG within a cell being a measurement of oxidative stress. The role of the polypeptide IK34720 (SEQ ID NO: 3) in UV-induced oxidative stress was assessed using the following protocol.

[0253] Female Skh: hr1 hairless mice were exposed to solar simulated UV-irradiation (UVR) by exposure to one fluorescent UVB tube (Philips TL40W 12R/S, Eindhoven, The Netherlands) in combination with 6 UVA tubes (Hitachi 40W F40T 10/BL, Tokyo, Japan). The UVA and UVB irradiation was filtered through a 0.125 mm cellulose acetate sheet (Grafix Plastics, Cleveland, OH) as previously described (Dixon K M et al., Biochem Mol Biol, 2007, 103 (3-5): 451-6). UV-irradiated mice were subjected to a single exposure equal to three times the minimal erythema dose (MED) of UVR (3.98 kJ/m² UVB and 63.8 kJ/m² UVA). Irradiated animals were randomly allocated to 5 treatment groups ($n=3$ per group).

[0254] Immediately following irradiation, mice in each treatment group for assessing oxidative stress were treated topically on the dorsal surface with either vehicle (base lotion containing ethanol, propylene glycol and water to a final solvent ratio of 2:1:1 respectively), 11.4 pmol/cm² of Calcitriol ("1,25(OH)₂D₃"), or a treatment of 20 μ g, 100 μ g or 200 μ g the polypeptide IK34720 (SEQ ID NO: 3) in 100 μ L of aqueous solution.

[0255] Biopsies were taken from UV-irradiated dorsal skin 3 h post-UVR and fixed in Histochoice fixative (Amresco, Solon OH) for 6 h. Skin samples were paraffin-embedded and 5 micrometre sections were cut for all analyses. Sections were subjected to routine hematoxylin and eosin staining for visualization of sunburn cells at 40x magnification, and the number of sunburn cells per linear millimetre of skin section recorded.

[0256] Levels of 8-oxo-2'-deoxyguanosine (8oxodG) indicative of oxidative stress were detected by immunohistochemistry and image analysis (Dixon K M et al., Cancer Prev Res 2011, 4 (9): 1485-94) as set out below.

[0257] Slides were deparaffinised and rehydrated in a series of graded ethanol solutions. Antigen retrieval was performed using Proteinase K at 37° C. for 30 minutes, followed by treatment of sections with 2 N HCl (in 70% ethanol) for 15 minutes and subsequently 50 mM Tris buffer for a further 15 minutes. For 8oxodG, slides were further treated with RNase A at 200 μ g/mL (Amresco, Ohio, USA) at 37° C. for 30 minutes. Subsequent steps were carried out using the Dako Animal Research Kit using the method prescribed by the manufacturer (Dako, Glostrup, Denmark). The anti-thymine dimer antibody (Sigma-Aldrich, Missouri, USA) was used at 10 μ g/mL to indicate DNA damage in the form of CPDs, while the 8oxodG antibody (Trevigen, Maryland, USA) was used at 2.5 μ g/mL to visualise oxidative stress.

[0258] As can be seen in the immunohistology presented in FIG. 5, and quantified in FIG. 6, the polypeptide IK34720

(SEQ ID NO: 3) inhibits 8-OHdG formation in the skin of Skh: hr1 mice following acute UV-irradiation. In FIG. 5, dark staining in nuclei indicates the presence of 8-oxo-dG [0259] The quantification of the immunohistological data for 8oxodG demonstrated that there was a statistically significant decrease in all treatment groups exposed to UV-irradiation compared to the vehicle (negative) control (**p<0.01, ****p<0.0001). No significant staining was observed with a monoclonal mouse IgG isotype used as an isotype staining control (data not shown).

[0260] This indicates the polypeptide RSKAKNPLYRRRRRRRRR, when applied topically to skin following UV-irradiation, decreases oxidative stress in skin cells induced by UV-irradiation.

EXAMPLE 5: The Polypeptide RSKAKNPLYRRRRRRRR, when Applied Topically to Skin Following UV-Irradiation, Decreases DNA Damage

[0261] FIGS. 7 and 8 illustrate the effect of the polypeptide IK34720 (SEQ ID NO: 3; "IK") on UV-induced DNA damage, as demonstrated by formation of Cyclobutane pyrimidine dimers (CPDs) in vitro.

[0262] Exposure to UV-radiation triggers a cascade of chemical reactions, and many molecular products (photoproducts) are formed that can inhibit polymerases, cause misreading during transcription or replication of DNA, or lead to arrest of replication. Cyclobutane pyrimidine dimers (CPD) are a common product of UV exposure and their concentration can quantify DNA damage.

[0263] An in vitro assay was conducted allowing for densitometry analysis of CPD detection by IHC in keratinocytes 3 h following UV-irradiation in accordance with the following protocol.

[0264] Keratinocytes were harvested and cultured as described above at Example 2. Samples were split into two groups, being UV irradiated (UVR) and non-UV irradiated (SHAM). UV-irradiation was performed by solar simulated UV-irradiation for cells, also as described above at Example 2. Irradiation solution was PBS containing 5 mM D-glucose.

[0265] Following irradiation, keratinocytes were treated with either Calcitriol, vehicle control (Veh) or the polypeptide IK34720 (SEQ ID NO: 3; "IK") at concentrations of 0.5 μ M, 1 μ M, 2.5 μ M or 5 μ M.

[0266] Harvested keratinocytes were plated on poly-D-lysine coated coverslips in 96 well plates and irradiated (or sham treated) as described above in at Example 2 in PBS containing 5 mM D-glucose. Keratinocytes were fixed 3 h after UV-irradiation. Immunohistochemistry and image analysis were performed as described previously (Gordon-Thomson et al., Photochem Photobiol Sci, 2012, 11 (12): 1837-47; Gupta et al., vide supra, Rybchyn M S et al., J Invest Dermatol, 2018; 138 (5): 1146-1156). Thymine dimers were detected using the anti-thymine dimer antibody (Sigma-Aldrich, Missouri, USA) at 10 μ g/mL, and quantified as an index of CPD, as previously described (Douki T and Cadet J, Biochemistry, 2001, 40 (8): 2495-501).

[0267] As shown in FIGS. 7 and 8, the polypeptide IK34720 (SEQ ID NO: 3—"IK", respectively) decreases CPD levels in primary keratinocytes exposed to solar simulated UV-irradiation in a dose dependent manner. Keratinocytes treated with 5 μ M of the polypeptide IK34720 (SEQ ID NO: 3) had a comparable reduction in CPD levels to keratinocytes treated with Calcitriol, and had a statistically signifi-

cant (*p<0.05) reduction in CPD levels compared to vehicle-treated UV-irradiated keratinocytes.

[0268] This data demonstrates the polypeptide IK34720 (SEQ ID NO: 3; "IK") reduces DNA damage in primary keratinocytes following exposure to UV-irradiation.

[0269] In FIG. 8B, CPD was calculated in terms of average intensity of CPD staining. Importantly, FIG. 8B demonstrates that at 10 μ M, the polypeptide IK34720 (SEQ ID NO: 3; "IK") is more effective at inhibiting CPD formation than the positive control 1,25D.

[0270] FIGS. 9 and 10 illustrate the effect of the polypeptide IK34720 (SEQ ID NO: 3; "IK") on UV-induced DNA damage, as demonstrated by formation of Cyclobutane pyrimidine dimers (CPDs) in vitro, in accordance with the following protocol.

[0271] Female Skh: hr1 hairless mice were exposed to solar simulated UV-irradiation as described above at Example 4. Immediately after irradiation mice were treated topically on the dorsal surface also as described in Example 4. Subsequently, skin was fixed at 3 hours post-UVR, and subjected to immuno-histochemical staining using the antibody directed against thymine dimers (CPD) described above at 10 μ g/ml. No significant staining was observed with a monoclonal mouse IgG isotype control (not shown). In FIG. 9, dark staining in nuclei indicates the presence of thymine dimers (CPD), and the % area stained is presented. Immunohistology was quantified as per Example 4.

[0272] As can be seen in the immunohistology presented in FIG. 9A, and quantified in FIG. 10, the polypeptide IK34720 (SEQ ID NO: 3) inhibits CPD formation in the skin of Skh: hr1 mice following acute UV-irradiation.

[0273] The quantification of the immunohistological data for CPD nuclei demonstrated that there was a statistically significant decrease in all treatment groups exposed to UV-irradiation compared to the vehicle (negative) control (** p<0.01, ***p<0.0001). No significant staining was observed with a monoclonal mouse IgG isotype used as an isotype staining control (data not shown).

[0274] This indicates the polypeptide RSKAKN-PLYRRRRRRRRR, when applied topically to skin following UV-irradiation, decreases DNA damage, as measured by the formation of CPD nuclei in skin cells induced by UV-irradiation.

**EXAMPLE 6: The Polypeptide
RSKAKN-PLYRRRRRRRRR, when Applied
Topically to Skin Following UV-Irradiation,
Reduces the Number of Apoptotic Cells**

[0275] FIG. 11 illustrates the effects of the polypeptide IK34720 (SEQ ID NO: 3) on cell apoptosis following UV-irradiation.

[0276] UV-induced DNA damage in the form of elevated CPDs can induce mutations in epidermal cells leading to the development of cancer cells. Reduction of CPDs through application of DNA repair enzymes prevents the risk of UV-induced skin cancer and reduce the level of apoptotic cells following UV-induced damage. The number of apoptotic skin cells following UV-irradiation was assessed in accordance with the following protocol.

[0277] Female Skh: hr1 hairless mice were prepared, irradiated and biopsied according to the methods of Example 4. Prior to biopsy, and immediately after irradiation, mice were treated with either a base lotion vehicle (negative control), 11.4pmol/cm² of Calcitriol in vehicle (positive

control) the polypeptide IK34720 (SEQ ID NO: 3) in water, at 20 μ g, 100 μ g or 200 μ g in a total volume of 100 μ L.

[0278] Biopsies were taken from UV-irradiated dorsal skin 3 hrs post-UVR and fixed in Histochoice fixative (Amresco, Solon OH) for 6 h. Skin samples were paraffin-embedded and 5 micrometre sections were cut for all analyses. Sections (24 h after UV) were subjected to routine hematoxylin and eosin staining for visualization of sunburn cells. The stained sections were examined under a Zeiss-Axioplan light microscope at 40 \times magnification, and the number of sunburn cells per linear millimetre of skin section recorded.

[0279] As shown in FIG. 11, the topical application of the polypeptide IK34720 (SEQ ID NO: 3) reduced the number of apoptotic keratinocytes following UV-irradiation.

[0280] This data demonstrates the polypeptide IK34720 (SEQ ID NO: 3) reduces keratinocyte apoptosis following exposure to UV-irradiation.

**EXAMPLE 7: The Polypeptide
RSKAKN-PLYRRRRRRRRR, when Applied
Topically to Human Skin Following UV-Irradiation
Damage, Decreases DNA Damage, and Reduces
the Number of Apoptotic Sunburn Cells**

[0281] FIGS. 12 and 13 illustrate the effect of the polypeptide IK34720 (SEQ ID NO: 3) on UV-induced DNA damage, as demonstrated by formation of CPDs in human explants, in accordance with the following protocol.

[0282] Human skin removed at elective surgery was cleaned, dissected and cut into pieces of approx. 5 mm \times 5 mm. Each piece was placed in a well of a 96 well plate, with individual plates prepared to assess the effects 3 hrs post treatment. All samples were performed in triplicate for each treatment. Skin was subjected to UV-radiation from solar-simulated UV source for 1.5 h (UVR), or non-irradiation (SHAM). Given that human skin is thicker than mouse skin, human skin explants were exposed to a radiation dose three times higher than that used for mouse skin, i.e., 20 J/cm² versus 7 J/cm², respectively, and the output spectrum of the laboratory solar simulator has previously been reported (Rybchyn M S et al, J Invest Dermatol. 2018 May; 138 (5): 1146-1156) and treated immediately after with a vehicle control, Calcitriol (1 nM) or the polypeptide IK34720 (SEQ ID NO: 3) at concentrations of 50 μ M, 250 μ M or 500 μ M.

[0283] Samples harvested at 3 hrs were fixed, section, stained and quantified as described in Example 5.

[0284] As can be seen in the immunohistology presented in FIG. 12, UV-irradiation increases the number of cells having CPDs (illustrated as dark spots) in all irradiated group 3 hrs post irradiation/treatment, with samples treated with Calcitriol or varying concentrations of the polypeptide IK34720 (SEQ ID NO: 3) having fewer stained cells. This data is quantified in FIGS. 13A and B for two individuals where the percentage of CPD positive cells was statistically significantly reduced when treated with 500 μ M of the polypeptide IK34720 (SEQ ID NO: 3).

[0285] This indicates the polypeptide RSKAKN-PLYRRRRRRRRR, when applied topically to skin following UV-irradiation, can reduce the formation of CPD in human skin explants following acute UV-irradiation at 3 hours post irradiation. This also confirms the mouse results presented in FIGS. 9 and 10.

[0286] FIGS. 14 and 15 illustrate the effect of the polypeptide IK34720 (SEQ ID NO: 3) on the number of apoptotic cells in human skin explants.

[0287] Skin explants were cultured irradiated and treated as described above for CPD, and subsequent to treatment were stained and quantified as described for Example 6.

[0288] FIG. 14 shows the number sunburn cells per mm of epidermis of human skin explants 3 hours post UV-irradiation in the various treatment groups. FIG. 15 shows the number sunburn cells per mm of epidermis of human skin explants 24 hours post UV-irradiation in the various treatment groups.

[0289] As shown in FIGS. 14 and 15, treatment with 50 μ M and 250 μ M of the polypeptide IK34720 (SEQ ID NO: 3) reduces the number of apoptotic cells 3 hrs and 24 hrs post UV-irradiation, and treatment with 500 μ M of the polypeptide IK34720 (SEQ ID NO: 3) statistically significantly reduces the number of apoptotic cells 3 hrs and 24 hrs post UV-irradiation.

[0290] The present inventors have also demonstrated that treatment with 80 μ M, 400 μ M and 800 μ M of the polypeptide IK34720 (SEQ ID NO: 3) statistically significantly reduces the number of apoptotic cells following UV-irradiation (data not shown).

[0291] This data indicates that the polypeptide IK34720 (SEQ ID NO: 3) reduces the number of apoptotic sunburn cells when applied topically to skin following UV-irradiation.

EXAMPLE 8: The Polypeptide
RSKAKNPLYRRRRRRRRR Inhibits Matrix
Metalloproteinase-1 (MMP-1) Activity In Vitro and
in Human Skin Explants

[0292] UV-induced skin damage initiates elevated MMP-1 in human skin cells that can lead to destruction of collagen, which is a hallmark of photoaging. It is known that the major enzyme responsible for collagen I digestion, matrix metalloproteinase 1 (MMP-1) is induced by exposure to sunlight (Dong K K et al, Exp Dermatol, 2008, 17 (12): 1037-44).

[0293] The effect of the polypeptide IK34720 (SEQ ID NO: 3) on MMP-1 activity was evaluated using the following protocol.

[0294] Human rheumatoid synovial fibroblast MMP-1 proenzyme, activated with APMA for 60 minutes at 37° C., was used as an active enzyme. The polypeptide IK34720 (SEQ ID NO: 3) at a concentration of 5 μ M, 10 μ M 800 μ M and 1000 μ M was pre-incubated with 8 nM activated enzyme in modified MOPS buffer pH 7.2 for 60 minutes at 37° C. The reaction was initiated by addition of 4 mM Mc-Pro-Leu-Gly-Leu-Dap-Ala-Arg followed by a 2 hour incubation period. Determination of the amount of Mca-Pro-Leu-Gly formed was read spectrofluorimetrically at 340 nm/400 nm.

[0295] FIG. 16 illustrates the effect of the polypeptide IK34720 (SEQ ID NO: 3) on the activity of MMP-1 in vitro, and FIGS. 17 and 18 illustrate the effect of the polypeptide IK34720 (SEQ ID NO: 3) in human skin explants following UV-induced skin damage.

[0296] As can be seen in FIG. 16, the polypeptide IK34720 (SEQ ID NO: 3) inhibits MMP-1 activation in a dose dependent manner. This data indicates that the polypeptide IK34720 (SEQ ID NO: 3) can be used to reduce photoaging over time.

[0297] The effect of the polypeptide IK34720 (SEQ ID NO: 3) on MMP-1 activity in human skin was evaluated using the following protocol.

[0298] FIGS. 17 and 18 illustrate the effect of the polypeptide IK34720 (SEQ ID NO: 3) on MMP1 expression, in accordance with the following protocol.

[0299] Human skin (2 \times human explant tissues) removed at elective surgery was cleaned, dissected and cut into pieces of approx. 5 mm \times 5 mm. Each piece was placed in a well of a 96 well plate, with individual plates prepared to assess the effects 3 hrs post treatment. Skin was subjected to UV-irradiation from solar-simulated UV source for 1.5 h (UVR), or non-irradiation (SHAM), and treated immediately after with a vehicle control, Calcitriol (1 nM) or the polypeptide IK34720 (SEQ ID NO: 3) at concentrations of 50 μ M, 250 μ M or 500 μ M. In FIG. 17, IK50, IK250 and IK500 as μ M concentrations refers to 15 μ g, 75 μ g and 150 μ g of IK34720 per 120 μ L culture medium/explant, respectively.

[0300] Samples harvested at 3 hrs were fixed, sectioned, immunohistochemically stained for MMP1 and quantified for MMP1 expression, by expressing epidermal area stained for MMP1 as a function of total epidermal area examined.

[0301] As can be seen in the immunohistology presented in FIG. 17, UV-irradiation increases the number of cells staining for MMP-1 activity (illustrated as dark spots) in all irradiated groups 3 hrs post irradiation/treatment, with samples treated with Calcitriol or varying concentrations of the polypeptide IK34720 (SEQ ID NO: 3) having fewer stained cells. No significant staining was observed with a monoclonal mouse IgG isotype used as an isotype staining control (data not shown).

[0302] This data is quantified in FIG. 18 for the explants where the percentage of MMP1 positive cells is statistically significantly reduced when treated with 500 μ M of the polypeptide IK34720 (SEQ ID NO: 3). This indicates the polypeptide RSKAKNPLYRRRRRRRR, when applied topically to skin following UV-irradiation, decreases MMP1 expression induced by UV-irradiation.

EXAMPLE 9: The Polypeptide
RSKAKNPLYRRRRRRRR Inhibits UV-Induced
Lipid Peroxidation in Dermal Skin Fibroblasts Cell
Lysates

[0303] Polyunsaturated fatty acids (lipids) are frequently used in cosmetics as soaps, skin care lotions and creams, after-shaves, make-up removers, etc. because in contrast to saturated lipids they help to maintain the skin's natural oil barrier. Moreover, the less saturated a lipid is the higher is the liquidity of the lipid. However, unsaturated lipids are more prone to oxidation from agents such as UV-irradiation and hence anti-oxidants, e.g., vitamins, are often added to skin care formulations.

[0304] Oxidising agents can alter lipid structure, creating lipid peroxides that result in the formation of malondialdehyde which can be measured as thiobarbituric acid-reactive substances (TBARS).

[0305] As shown in Example 4, the polypeptide RSKAKNPLYRRRRRRRR when applied topically to skin following UV-irradiation decreases UV-induced oxidative stress in the skin.

[0306] The ability of the polypeptide RSKAKNPLYRRRRRRRR to alter UV-induced oxidative damage of cell-derived lipids was examined using the TBARS thiobarbituric acid-reactive substances (TBARS) lipid peroxidation assay.

[0307] After irradiation or sham-irradiation of dermal fibroblasts, supernatants (900 μ L) were collected. In brief,

90 µL of butylated hydroxytoluene (2% w/w in ethanol) was added and samples kept frozen (-20° C.) until the TBARS assay. Petri dishes were washed twice with 1 mL of HBSS, cells scraped in 600 µL of water and 60 µL of 0.5% aqueous Triton X100 added to this solution, for protein determination carried out by the Lowry method (Lowry O H et al, J. Biol. Chem., 1951, 193:265-275). TBARS were fluorometrically assayed as described (Morlière P et al, Biochim. Biophys. Acta, 1991, 1084:261-268). Briefly, thawing samples were heated in the presence of thiobarbituric acid in acidic conditions, and TBARS extracted with 1-butanol and fluorometrically quantified ($\lambda_{exc}=515$ nm and $\lambda_{em}=550$ nm). Tetraethoxypropane, which quantitatively yields the malondialdehyde-thiobarbituric acid adduct in the assay conditions, was used for calibration. TBARS values, expressed in malondialdehyde (MDA) equivalents, were normalized to the cell protein for each Petri dish. Each TBARS determination was performed in triplicate (e.g., with three Petri dishes per data point).

[0308] As can be seen in FIG. 19, UV-irradiation increases the number of TBA reactive substances (TRS) in all irradiated groups post irradiation/treatment. The significant difference in TRS between Sham and UV irradiation in the absence of treatment is not seen in the presence of either 1,25D or RSKAKNPLYRRRRRRRRR ("IK-3") at the highest concentration (5 µM) compared with lower doses of RSKAKNPLYRRRRRRRRR.

[0309] This indicates the polypeptide RSKAKN-PLYRRRRRRRRR, decreases UV-induced oxidative damage of cell-derived lipids in dermal skin fibroblast cell lysates.

EXAMPLE 10: Effect of IK14800 on Melanin Production

[0310] Melanoma induction by UVA requires melanin pigment and UVB irradiation initiates melanoma. A desirable effect of skin care products is to reduce skin pigmentation that occurs from sunlight exposure.

[0311] EXAMPLE 2 shows the polypeptide RSKAKN-PLYRRRRRRRRR inhibits pCREB formation in primary keratinocytes when applied following keratinocyte exposure to solar simulated UV-irradiation. Phosphorylated CREB induces activation of the microphthalmia (MITF) transcription factor, which is a myc-like master transcription factor that, in melanocytes, drives expression of tyrosinase and other pigment biosynthetic enzymes.

[0312] The ability of the polypeptide RSKAKN-PLYRRRRRRRRR to alter melanin production was examined.

[0313] In brief, MM1418-C1 lightly pigmented melanoma cells or human primary melanocytes were grown in 24 well culture plates and treated with 10 µM

[0314] RSKAKNPLYRRRRRRRRR ("IK-3") for 24 hours prior to being exposed to 2 kJ/m² UVB radiation. Controls (not treated with RSKAKNPLYRRRRRRRRR) labelled "Con" and "UVB", respectively, were exposed to either 0 or 2 kJ/m² UVB radiation. Cell groups were returned to the incubator for 24 hours and then the levels of melanin and protein in the cells were measured spectrophotometrically. In each experiment triplicate samples were measured. Data shown in FIG. 19 indicate the average values+SEM (µg melanin/mg cell protein) exposed to 0 or 2 kJ/m² UVB which had been pre-treated with 0 or 10 µM of RSKAKNPLYRRRRRRRRR 24 hours prior to being

exposed to UVB radiation. The t-test (2-tailed) was used to determine statistical significance, *p<0.05, ***p<0.001.

[0315] As can be seen in FIG. 20A, UVB-irradiation significantly increases the melanin content of melanoma cells. Importantly, cells treated with RSKAKN-PLYRRRRRRRRR prior to UVB treatment show significantly decreased melanin content, relative to cells not treated with RSKAKNPLYRRRRRRRRR.

[0316] As can be seen in FIG. 20B, UVB-irradiation significantly increases the melanin content of human primary melanocytes. Importantly, cells treated with RSKAKNPLYRRRRRRRRR prior to UVB treatment show significantly decreased melanin content, relative to cells not treated with RSKAKNPLYRRRRRRRRR.

[0317] This indicates the polypeptide RSKAKN-PLYRRRRRRRRR, decreases melanin induction by UVB.

[0318] All methods described herein can be performed in any suitable order unless indicated otherwise herein or clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the example embodiments and does not pose a limitation on the scope of the claimed invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential.

EXAMPLE 11: The Polypeptides RSKAKNPLY (IK94000) and RRRRRRRRR (IK00900), and RSKAKNPLYRRRRRRRRR, when Applied Topically to Skin Following UV-Irradiation, Decrease DNA Damage

[0319] FIG. 21 illustrates the effect of the polypeptides IK34720 (SEQ ID NO: 3; "IK"; "IK14800" RSKAKN-PLYRRRRRRRRR), RSKAKNPLY (IK94000) and RRRRRRRRR (IK00900), on UV-induced DNA damage, as demonstrated by formation of Cyclobutane pyrimidine dimers (CPDs) in vitro.

[0320] As discussed above, exposure to UV-radiation triggers a cascade of chemical reactions, and many molecular products (photolesions) are formed that can inhibit polymerases, cause misreading during transcription or replication of DNA, or lead to arrest of replication. Cyclobutane pyrimidine dimers (CPD) are a common product of UV exposure and their concentration can quantify DNA damage.

[0321] An in vitro assay was conducted allowing for densitometry analysis of CPD detection by IHC in keratinocytes 3 h following UV-irradiation in accordance with the following protocol.

[0322] Keratinocytes were harvested and cultured as described above at Example 2. Samples were split into two groups, being UV irradiated (UVR) and non-UV irradiated (SHAM). UV-irradiation was performed by solar simulated UV-irradiation for cells, also as described above at Example 2. Irradiation solution was PBS containing 5 mM D-glucose.

[0323] Following irradiation, keratinocytes were treated with either Calcitriol, vehicle control (Veh) or the polypeptide IK34720 (SEQ ID NO: 3; "IK") IK14800; (RSKAKN-PLYRRRRRRRRR), RSKAKNPLY (IK94000) and RRRRRRRRR (IK00900), at concentrations of 5 µM.

[0324] Harvested keratinocytes were plated on poly-D-lysine coated coverslips in 96 well plates and irradiated (or sham treated) as described above in at Example 2 in PBS containing 5 mM D-glucose. Keratinocytes were fixed 3 h after UV-irradiation. Immunohistochemistry and image

analysis were performed as described previously (Gordon-Thomson et al., Photochem Photobiol Sci, 2012, 11 (12): 1837-47; Gupta et al., *vide supra*, Rybchyn M S et al., J Invest Dermatol, 2018; 138 (5): 1146-1156). Thymine dimers were detected using the anti-thymine dimer antibody (Sigma-Aldrich, Missouri, USA) at 10 µg/ml, and quantified as an index of CPD, as previously described (Douki T and Cadet J, Biochemistry, 2001, 40 (8): 2495-501).

[0325] As shown in FIG. 21, the polypeptides RSKAKN-PLY (IK94000) and RRRRRRRRR (IK00900) decrease CPD levels in primary keratinocytes exposed to solar simulated UV-irradiation in the same manner as IK34720 (SEQ ID NO: 3-“IK”, respectively). Keratinocytes treated with 5 µM of the polypeptide IK34720 (SEQ ID NO: 3) had a comparable reduction in CPD levels to keratinocytes treated with Calcitriol, and had a statistically significant (*p<0.05) reduction in CPD levels compared to vehicle-treated UV-irradiated keratinocytes.

[0326] Keratinocytes treated with 5 µM of the polypeptide RSKAKNPLY (IK94000) had a comparable reduction in CPD levels to keratinocytes treated with Calcitriol, and had a statistically significant (*p<0.05) reduction in CPD levels compared to vehicle-treated UV-irradiated keratinocytes.

[0327] Keratinocytes treated with 5 µM of the polypeptide RRRRRRRRR (IK00900) had a comparable reduction in CPD levels to keratinocytes treated with Calcitriol, and had a statistically significant (*p<0.05) reduction in CPD levels compared to vehicle-treated UV-irradiated keratinocytes.

[0328] This data demonstrates the polypeptides IK34720 (SEQ ID NO: 3; “IK”); RSKAKNPLY (IK94000) and RRRRRRRRR (IK00900) reduce DNA damage in primary keratinocytes following exposure to UV-irradiation.

EXAMPLE 12: The Polypeptide
RSKAKNPLYRRRRRRRRR Reverses HEV Light
Induced Damage to Human Keratinocytes

[0329] The ability of the polypeptide RSKAKN-PLYRRRRRRRRR, to reverse HEV light (“blue light”) induced damage to human keratinocytes was examined. In brief, Human Epidermal Keratinocytes (NHEK) which are representative of the epidermis were exposed to HEV light in the presence of the polypeptide RSKAKN-PLYRRRRRRRRR, or untreated in the presence of the polypeptide RSKAKNPLYRRRRRRRRR.

[0330] The expression of Aquaporin 3 in cells (e.g. aquaporin 3 positive cells) was measured. Aquaporin 3 is found in the basolateral cell membrane and provides a pathway for water to exit cells. It is expressed in various tissues including the skin.

[0331] The experiment was carried out in quintuplicate in the following conditions (n=5):

- [0332] Untreated NHEK
- [0333] NHEK+IK14800 2.5 µM
- [0334] NHEK+IK14800 5 µM
- [0335] NHEK+IK14800 10 µM
- [0336] NHEK+Blue light
- [0337] NHEK+Blue light+IK14800 2.5 µM
- [0338] NHEK+Blue light+IK14800 5 µM
- [0339] NHEK+Blue light+IK14800 10 µM

[0340] Chronic blue light irradiation: one exposure per day for 3 days (220 joules—wavelength 470 nm). 4 days of treatment with the peptide (24 h before exposure to blue light and during the 3 days. The peptide was resuspended in milliQ water then diluted in the cell culture medium.

[0341] After treatment, the cells were washed and fixed with Formalin. After permeabilization, the cells were incubated with an anti-Aquaporin 3 antibody revealed with a secondary antibody linked to an Alexa.

[0342] Finally, the nuclei were labelled with DAPI. The labelled proteins were observed and quantified by automated fluorescence microscopy Cellinsight CX7 High-Content Screening Platform (Thermofischer Data analysis

[0343] A statistical analysis was performed using Mann-Whitney by Prism software. The significance is correlated with the p-value: ns=no significant, *p-value<0.5, **p-value<0.01, ***p-value<0.001.).

[0344] FIG. 22 shows the polypeptide RSKAKN-PLYRRRRRRRRR significantly increases the number of Aquaporin 3 positive cells in keratinocytes exposed to HEV light: +20% with IK14800 at 5 µM and +27% with IK14800 at 10 µM. The peptide restores the basal expression of Aquaporin 3 in a dose dependent manner.

[0345] This data demonstrates the polypeptide RSKAKN-PLYRRRRRRRRR reverses HEV light induced damage to human keratinocytes in primary keratinocytes following exposure to UV-irradiation. In particular, the polypeptide RSKAKNPLYRRRRRRRRR reverses HEV light induced reduction in AQP3 levels in human keratinocytes.

EXAMPLE 13: The Polypeptide
RSKAKNPLYRRRRRRRRR Reverses HEV Light
Induced Damage to Human Keratinocytes

[0346] The ability of the polypeptide RSKAKNPLY (SEQ ID NO: 5) and the polyarginine amino acid sequence region RRRRRRRRR (SEQ ID NO: 6) to reverse HEV light (“blue light”) induced damage to human keratinocytes is also examined. In brief, Human Epidermal Keratinocytes (NHEK) which are representative of the epidermis were exposed to HEV light in the presence of the polypeptide

[0347] RSKAKNPLY (SEQ ID NO: 5) or the polyarginine amino acid sequence region RRRRRRRRR (SEQ ID NO: 6), or untreated in the presence of the polypeptide the polypeptide RSKAKNPLY (SEQ ID NO: 5) or the polyarginine amino acid sequence region RRRRRRRRR (SEQ ID NO: 6) as per the protocol of Example 12.

EXAMPLE 14: Biological Evaluation of the
Moisturizing Effect of Polypeptides
RSKAKNPLYRRRRRRRRR, RSKAKNPLY and
RRRRRRRRR, when Applied Topically to Human
Skin

[0348] The moisturising effect of IK-3/IK14800 (also referred to herein as IK34720) (SEQ ID NO: 3) was examined using the following protocol.

[0349] In brief, 11 female adult subjects aged between 18 and 60 years old were selected. Subjects had dry to very dry skin on the forearms (cutaneous hydration rate 35-50 A.U. for dry skin and <35 A.U. for very dry skin, verified using Corneometer®):

Inclusion Criteria:

- [0350] Sex: female;
- [0351] Age: between 18 and 60 years old;
- [0352] Phototype: I to IV;

[0353] Subjects with dry to very dry skin on the forearms (cutaneous hydration rate 35-50 A.U. for dry skin and <35 A.U. for very dry skin, verified using Corneometer®);

[0354] Subjects without hair on the inner side of the forearms.

[0355] Healthy subject;

[0356] Subject having given her free informed, written consent.

Study Requirements and Constraints:

DURING THE STUDY, THE SUBJECTS

HAVE TO	MUST NOT
comply with dates and hours of evaluation measurements; remain in the special conditions of temperature and humidity in the waiting room during the visits at the laboratory; have forearms exposed and not crossed, sleeves rolled up during the visits at the laboratory; wear mask and protective gloves during the visits at the laboratory.	apply any product to test areas the day of the visit* to the lab; apply any other similar product to test areas during the whole study; wash or wipe tested areas during the whole study; eat, drink (except the guaranteed meal) and smoke during the visits at the laboratory.

Test Products:

References	Forms	Packagings	Confidentiality procedure	Storage temperature
IK-3 CREAM 50 g 0.1% w/w	White emulsion	1 sample of 50 g	Encoded	Room temperature
Aqueous Cream APF Base Control	White emulsion	1 sample of 50 g	Encoded	Room temperature

Application:

References	Zone	Frequency	Directions for use
IK-3 CREAM 50 g 0.1% w/w	Defined treated zone on the forearms.	At the laboratory. Single standardized application (2 µl/cm ²) of each product.	Light, uniform massage with a fingerstall.
Aqueous Cream APF Base Control (As per IK-3 cream)			

Study Stages:

At t0:

Subjects:

[0357] come to the laboratory without having applied any product to the forearms since the previous evening;

[0358] are informed about the trial objectives, the procedures and the risks of the study;

[0359] sign two copies of the Consent Form;

[0360] acclimatize during about 30 minutes in the air-conditioned waiting room, the forearms being bared.

Technician:

[0361] conducts an epidemiological interview;

[0362] verifies the inclusion and exclusion criteria;

[0363] defines three zones on the forearms for Corneometer® measurements, according to the randomization list, in brief:

[0364] two treated zones, each zone treated by one studied product,

[0365] one non-treated zone being the control;

[0366] measures the cutaneous hydration rate using Corneometer® on three previously defined zones;

[0367] applies the products to the previously defined treated zones.

At t30', t2h, t4h, t6h and t8h after the product application:
Technician:

[0368] measures the cutaneous hydration rate using Corneometer® on three zones defined at t0;

[0369] gives to the subjects:

[0370] the daily log to write down their possible unpleasant sensations or medications.

[0371] At t24h after the products application:

Subjects:

[0372] come to the laboratory without having applied any product to the forearms and without having washed the forearms since DO;

[0373] bring back their daily log;

[0374] acclimatize during about 30 minutes in the air-conditioned waiting room, the forearms being bared.

Technician:

- [0375] analyses the daily log and records the possible adverse reactions;
- [0376] measures the cutaneous hydration rate using Corneometer® on three zones defined at t0.

Ambient Conditions During Measurements:

- [0377] room temperature: 22±2° C.;
- [0378] relative humidity: between 35% and 55%.

Remarks:

- [0379] before each measurement each zone is wiped three times with a tissue paper (concerns the studied part of the zone at each kinetic);
- [0380] a standardized meal is served to the subjects who remain 8 hours at the laboratory on DO;
- [0381] the probe of Corneometer® is disinfected after each subject.

Data Analysis:

- [0382] The following data are analysed:

Parameter(s)	Unit(s)	Variation(s) $t_i - t_0$ Kinetics	Statistical analysis (tick if yes)	Expected result(s)
Corneometer ®	Hydration rate	A.U. $t_i - t_0$ ($i = t30'$, $t2$ h, $t4$ h, $t6$ h, $t8$ h, $t24$ h)	X	↗: moisturizing effect ↘: non-drying effect
Record of the possible adverse reactions	Functional and physical signs	/	/	/

Legend:

A.U.: arbitrary units

[0383] Individual data are presented in raw value tables. These tables also show the descriptive statistics: means, medians, minima, maxima, standard errors of the means (SEM) and confidence intervals of 95% (95% CI).

[0384] Variation tables present raw variations, percentage variations, descriptive statistics and the results of the statistical analysis (p).

[0385] The variations (Δ) and in percentage on the mean ($\Delta\%$) are calculated according to the following formulas.

Comparison Treated Zone /Non-treated Zone:

Treated zone	Non-treated zone
$\Delta TZ = (TZ_{ti} - TZ_{t0})$	$\Delta NTZ = (NTZ_{ti} - NTZ_{t0})$
$\Delta\% TZ = \frac{(TZ_{ti} - TZ_{t0})}{TZ_{t0}} \times 100$	$\Delta\% NTZ = \frac{(NTZ_{ti} - NTZ_{t0})}{NTZ_{t0}} \times 100$
$\Delta\Delta = \Delta TZ - \Delta NTZ$	
$\Delta\Delta\% = \Delta\% TZ - \Delta\% NTZ$	


with:
 TZ: value obtained on the zone treated by the tested product
 NTZ: value obtained on the non-treated zone
 t0: before product application
 ti: at each measurement time after product application

Comparison between the products:

Product 1	Product 2
$\Delta Pdt1 = (Pdt1_{ti} - Pdt1_{t0})$	$\Delta Pdt2 = (Pdt2_{ti} - Pdt2_{t0})$
$\Delta\% Pdt1 = \frac{(Pdt1_{ti} - Pdt1_{t0})}{Pdt1_{t0}} \times 100$	$\Delta\% Pdt2 = \frac{(Pdt2_{ti} - Pdt2_{t0})}{Pdt2_{t0}} \times 100$
$\Delta\Delta = \Delta Pdt1 - \Delta Pdt2$	
$\Delta\Delta\% = \Delta\% Pdt1 - \Delta\% Pdt2$	

with:
 Pdt1: value obtained on the zone treated by the tested product "1"
 Pdt2: value obtained on the zone treated by the tested product "2"
 t0: before product application
 ti: at each measurement time after product application


Statistical method:



Analysis conditions	p-value	H0	Conclusion
Type I error (α) = 5% in bilateral mode	$p \leq 0.05$	Rejected	Statistically significant difference
Null hypothesis ($H0$) = no difference between means ⁽¹⁾ or medians ⁽²⁾	$p > 0.05$	Not rejected	No statistically significant difference

[0386] Cutaneous hydration measurements are performed with a Corneometer® CM 825 (COURAGE & KHAZAKA). The measuring principle is based on capacitance measurement. The surface of the measurement head, in contact with the skin, modifies its electrical capacity according to the humidity level of the skin.

[0387] This technique is a well-established method to reproducibly and accurately determine the hydration level of the skin surface, i.e. the humidity level of the most external cutaneous layers of the Stratum Corneum (10-20 µm depth).



[0388] Table 2 shows a synthesis of the results with IK-3 cream 50 g 0.1% w/w RSKAKNPLYRRRRRRRR ("IK-3") in Aqueous Cream APF Base, presented as variation of the cutaneous hydration rate after a single standardized application of the product (in comparison to a non-treated zone):

TABLE 2

		$\Delta\Delta Tx - T0$	Statistic	p	Significativity	% of efficacy	% of subjects presenting an improvement
Parameter	Kinetics	(mean \pm SEM)					
IK-3	Cutaneous hydration rate	$\Delta t30'$		<0.0001	Yes	+68%	100%
CREAM 50 g 0.1% w/w		$\Delta t2 h$		<0.0001	Yes	+84%	100%
		$\Delta t4 h$		<0.0001	Yes	+66%	100%
		$\Delta t6 h$		<0.0001	Yes	+52%	100%
		$\Delta t8 h$		<0.0001	Yes	+45%	100%
		$\Delta t24 h$		<0.0001	Yes	+27%	100%

[0389] FIG. 23 shows variations in cutaneous hydration rate following IK-3 cream application. FIG. 24 shows the evolution of cutaneous hydration rate on treated (IK-3 cream) and non-treated zones. These data demonstrate that in comparison to a non-treated zone, the product "IK-3 CREAM 50 g 0.1% w/w" presented a significant very long-lasting moisturizing effect of epidermis superficial layers thirty minutes, two, four, six and eight hours after its single standardized application: increase in cutaneous hydration rate of 68% at t30', 84% at t2h, 66% at t4h, 52% at t6h, 45% at t8h and 27% at t24h.

[0390] Table 3 shows a synthesis of the results with control (Aqueous Cream APF Base), presented as variation of the cutaneous hydration rate after a single standardized application of the product (in comparison to a non-treated zone):

TABLE 3

		$\Delta\Delta Tx - T0$	Statistic	p	Significativity	% of efficacy	% of subjects presenting an improvement
Parameter	Kinetics	(mean \pm SEM)					
Aqueous Cream APF	Cutaneous hydration rate	$\Delta t30'$		<0.0001	Yes	+71%	100%
Base Control		$\Delta t2 h$		<0.0001	Yes	+80%	100%
		$\Delta t4 h$		<0.0001	Yes	+64%	100%
		$\Delta t6 h$		<0.0001	Yes	+51%	100%
		$\Delta t8 h$		<0.0001	Yes	+42%	100%
		$\Delta t24 h$		0.0252	Yes*	+8%	73%

*not clinically significant increase of the cutaneous hydration rate (if mean ≤ 3)

[0391] FIG. 25 shows variations in cutaneous hydration rate following Aqueous Cream APF Base application. FIG. 26 shows the evolution of cutaneous hydration rate on control treated (Aqueous Cream APF Base) and non-treated zones. These data demonstrate that in comparison to a

non-treated zone, the product "Aqueous Cream APF Base" presented a significant long-lasting moisturizing effect of epidermis superficial layers thirty minutes, two, four, six and eight hours after its single standardized application and a non-drying effect of epidermis superficial layers twenty-four hours after its single standardized application: increase in cutaneous hydration rate of 71% at t30', 80% at t2h, 64% at t4h, 51% at t6h, 42% at t8h and 8% at t24h.

[0392] Table 4 shows a comparison the products 'IK-3 CREAM 50 g 0.1% w/w' and 'Aqueous Cream APF Base Control'

TABLE 4

Parameter	Kinetics	$\Delta\Delta T_x - T_0$	Statistic		$\Delta\% \text{ on the}$
		(mean \pm SEM)	p	Significativity	mean
IK-3 CREAM 50 g 0.1% w/w vs Aqueous Cream APF Base Control	Cutaneous hydration rate $\Delta\Delta t_{24} \text{ h}$	-1 \pm 2	0.7178	No	-4%
		1 \pm 2	0.5298	No	+5%
		0 \pm 2	0.8696	No	+2%
		0 \pm 2	0.9934	No	-0%
		1 \pm 1	0.6979	No	+6%
		6 \pm 1	<0.0001	Yes	+230%

[0393] FIG. 27 the evolution of cutaneous hydration rate comparing IK-3 cream and Aqueous Cream APF Base. These data demonstrate that after a single standardized application, the data analysis showed statistically significant difference between the products “IK-3 CREAM 50 g 0.1% w/w” and “Aqueous Cream APF Base Control” in favour of the product “IK-3 CREAM 50 g 0.1% w/w” at kinetic t24h. The increase in cutaneous hydration rate at t24h was significantly higher in product “IK-3 CREAM 50 g 0.1% w/w” than product “Aqueous Cream APF Base Control” of 230%, thus the product “IK-3 CREAM 50 g 0.1% w/w” showed better moisturizing effect at t24h.

[0394] The moisturising effect of RSKAKNPLY (SEQ ID NO: 5) and the polyarginine amino acid sequence region RRRRRRRRRR (SEQ ID NO: 6) are also examined suing the above protocol and analysis.

EXAMPLE 15: Evaluation of the Effect of Polypeptides RSKAKNPLYYRRRRRRRRR, RSKAKNPLY and RRRRRRRRR on Cytokine Production by UV Irradiated Keratinocytes

[0395] The ability of polypeptides RSKAKN-
PLYYRRRRRRRRR, RSKAKNPLY and RRRRRRRRR on cytokine production by UV irradiated keratinocytes is examined.

IL-10 Production

[0396] For this study normal primary human keratinocytes are used. Cultures of keratinocytes are exposed to either 40 KJ/m² UVA (365 nm) and/or 2 KJ/m² UVB (312 nm) radiation. The UV dose chosen represents that present in sunlight that causes 1 MED. The media in the culture wells are concentrated using microconcentrators, and the level of IL-10 present detected using a Human IL-10 ELISA kit. IL-10 levels are expressed as nmoles/mg cell protein. Cell protein levels are measured using the BCA protein kit. Prior to exposure to UV radiation the effect of IK14800 on cell viability will be measured using CCK-8 method. Cells are treated with 5, 10 or 20 μM IK14800 and cell viability

measured after 24 or 48 h. IK14800 (a dose that does not affect cell viability) is added to the cultures either (a) only for 24 h prior to exposure to UV radiation, (b) only following irradiation or (c) both pre- and post-irradiation. At the end of the experiment, cell viability is measured using trypan blue exclusion.

[0397] The experimental set up is as follows (Table 5):

TABLE 5

UV source	Treatment of UV-irradiated keratinocytes for IL-10 production			
	Control (PBS)	IK14800 (pre-exposure only)	IK14800 (post-exposure only)	IK14800 (pre & post exposure)
None	+	+	+	+
UVA	+	+	+	+
UVB	+	+	+	+
UVA + UVB	+	+	+	+

Experiments are set up in triplicate and repeated three times.

IL-12 Production

[0398] For this study normal primary human keratinocytes are used. Cultures of keratinocytes are exposed to either 40 KJ/m² UVA (365 nm) and/or 2 KJ/m² UVB (312 nm) radiation (as per Part A). The media in the culture wells is concentrated using microconcentrators, and the level of IL-12 present detected using a Human IL-12 ELISA kit. IL-12 levels are expressed as nmoles/mg cell protein. Cell protein levels are measured using the BCA protein kit. IK14800 (10 μM) will be added to the cultures either (a) only for 24 h prior to exposure to UV radiation, (b) only following irradiation or (c) both pre- and post-irradiation. At the end of the experiment, cell viability is measured using trypan blue exclusion.

[0399] The experimental set up is as follows (Table 6):

TABLE 6

UV source	Treatment of UV-irradiated keratinocytes to measure IL-12 production			
	Control (PBS)	IK14800 (pre-exposure only)	IK14800 (post-exposure only)	IK14800 (pre & post exposure)
None	+	+	+	+
UVA	+	+	+	+
UVB	+	+	+	+
UVA + UVB	+	+	+	+

Experiments are set up in triplicate and repeated three times.

TNF α Production

[0400] To examine whether enhancing IL-12 production, in turn, effects TNF α production by keratinocytes, TNF α production by keratinocytes is measured, and anti-IL-12 Ab used to examine the role played by IL-12.

[0401] For this study normal primary human keratinocytes are used. Cultures of keratinocytes are exposed to 2 KJ/m² UVB (312 nm) radiation. The media in the culture wells is concentrated using microconcentrators, and the level of TNF α present detected using a Human TNF ELISA kit. The TNF α levels are expressed as nmoles/mg cell protein. Cell protein levels are measured using the BCA protein kit. IK14800 (10 μ M) are added to the cultures 24 h prior to exposure to UV radiation, while Anti-IL-12 Ab (10 μ g/mL) is added immediately post-irradiation. It has been shown in other studies that IL-1 α stimulates TNF α production in irradiated keratinocytes and parallel experiments using cells treated with this cytokine are therefore performed. At the end of the experiment, cell viability is measured using trypan blue exclusion.

[0402] The experimental set up is as follows (Table 7):

TABLE 7

UV source	Treatment of UV-irradiated keratinocytes to measure TNF α production			
	Control (PBS)	IK14800 (pre-exposure only)	Anti-IL-12 Ab (post exposure)	IK14800 (pre-exposure) + Anti-IL-12 Ab (post exposure)
None	+	+	+	+
None + IL1 α	+	+	+	+
UVB	+	+	+	+
UVB + IL1 α	+	+	+	+

Experiments are set up triplicate and repeated three times.

[0403] The effect of RSKAKNPLY (SEQ ID NO: 5) and the polyarginine amino acid sequence region RRRRRRRRR (SEQ ID NO: 6) are also examined suing the above protocol and analysis.

[0404] The description provided herein is in relation to several embodiments which may share common characteristics and features. It is to be understood that one or more features of one embodiment may be combinable with one or more features of the other embodiments. In addition, a single feature or combination of features of the embodiments may constitute additional embodiments.

[0405] Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to, or indicated in this specification, individually or collectively, and any and all combinations of any two or more of the steps or features.

[0406] The subject headings used herein are included only for the ease of reference of the reader and should not be used to limit the subject matter found throughout the disclosure or the claims. The subject headings should not be used in construing the scope of the claims or the claim limitations.

[0407] Also, it is to be noted that, as used herein, the singular forms "a", "an" and "the" include plural aspects unless the context already dictates otherwise. As such, the terms "a" (or "an"), "one or more," and "at least one" are used interchangeably herein.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 11
<210> SEQ ID NO 1
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic polypeptide

<400> SEQUENCE: 1
Arg Ser Lys Ala Lys Asn Pro Leu Tyr Arg
1 5 10

<210> SEQ ID NO 2
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic polypeptide
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (1)..(10)
<223> OTHER INFORMATION: Dextro reverso

<400> SEQUENCE: 2
Arg Tyr Leu Pro Asn Lys Ala Lys Ser Arg
1 5 10

<210> SEQ ID NO 3
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic polypeptide

<400> SEQUENCE: 3
Arg Ser Lys Ala Lys Asn Pro Leu Tyr Arg Arg Arg Arg Arg Arg
1 5 10 15

Arg Arg

<210> SEQ ID NO 4
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic polypeptide
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (1)..(18)
<223> OTHER INFORMATION: Dextro reverso

<400> SEQUENCE: 4
Arg Arg Arg Arg Arg Arg Arg Tyr Leu Pro Asn Lys Ala Lys
1 5 10 15

Ser Arg

<210> SEQ ID NO 5
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic polypeptide

<400> SEQUENCE: 5

-continued

Arg Ser Lys Ala Lys Asn Pro Leu Tyr
1 5

<210> SEQ ID NO 6
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic polypeptide

<400> SEQUENCE: 6

Arg Arg Arg Arg Arg Arg Arg Arg Arg
1 5

<210> SEQ ID NO 7
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic polypeptide
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (1)..(9)
<223> OTHER INFORMATION: Dextro reverso

<400> SEQUENCE: 7

Tyr Leu Pro Asn Lys Ala Lys Ser Arg
1 5

<210> SEQ ID NO 8
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic polypeptide
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (1)..(9)
<223> OTHER INFORMATION: Dextro reverso

<400> SEQUENCE: 8

Arg Arg Arg Arg Arg Arg Arg Arg Arg
1 5

<210> SEQ ID NO 9
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic polypeptide
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (1)..(10)
<223> OTHER INFORMATION: Dextro reverso

<400> SEQUENCE: 9

Arg Ser Lys Ala Lys Asn Pro Leu Tyr Arg
1 5 10

<210> SEQ ID NO 10
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic polypeptide
<220> FEATURE:
<221> NAME/KEY: SITE

-continued

```

<222> LOCATION: (1)..(18)
<223> OTHER INFORMATION: Dextro reverso

<400> SEQUENCE: 10

Arg Ser Lys Ala Lys Asn Pro Leu Tyr Arg Arg Arg Arg Arg Arg
1           5          10          15

Arg Arg

<210> SEQ ID NO 11
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic polypeptide
<220> FEATURE:
<221> NAME/KEY: SITE
<222> LOCATION: (1)..(9)
<223> OTHER INFORMATION: Dextro reverso

<400> SEQUENCE: 11

Arg Ser Lys Ala Lys Asn Pro Leu Tyr
1           5

```

1. An isolated or purified polypeptide comprising the amino acid sequence RSKAKNPLY (SEQ ID NO: 5), or the dextro-reverso form of the amino acid sequence (ylpnkaksr; SEQ ID NO: 7), and/or a polyarginine amino acid sequence region.
2. An isolated or purified polypeptide according to claim 1 wherein the amino acid sequence RSKAKNPLY (SEQ ID NO: 5), or the dextro-reverso form of the amino acid sequence (ylpnkaksr; SEQ ID NO: 7), is adjacent the polyarginine amino acid sequence region.
3. An isolated or purified polypeptide according to claim 1 wherein the polyarginine amino acid sequence region is N-terminal and/or C-terminal of the amino acid sequence RSKAKNPLY (SEQ ID NO: 5), or the dextro-reverso form of the amino acid sequence (ylpnkaksr; SEQ ID NO: 7).
4. An isolated or purified polypeptide according to claim 1 wherein the amino acid sequence RSKAKNPLY (SEQ ID NO: 5), is N terminal to the polyarginine amino acid sequence region.
5. An isolated or purified polypeptide according to claim 1 wherein the amino acid sequence (ylpnkaksr; SEQ ID NO: 7), is C terminal to the polyarginine amino acid sequence region.
6. An isolated or purified polypeptide according to claim 1, wherein the polyarginine amino acid sequence region comprises 4 to 20 arginine residues.
7. An isolated or purified polypeptide according to claim 1, wherein the polyarginine amino acid sequence region comprises 98 arginine residues.
8. An isolated or purified polypeptide according to claim 1, wherein the polypeptide is modified at the C-terminus of the polypeptide.
9. An isolated or purified polypeptide according to claim 1 wherein the polypeptide is amidated at the C-terminus of the polypeptide.
- 10-42. (canceled)
43. A method for promoting wound healing, or treating and/or preventing a skin condition in a mammal, comprising

administering to the mammal an effective amount of a polypeptide comprising an isolated or purified polypeptide according to claim 1.

44. A method for promoting wound healing, or treating and/or preventing a skin condition in a mammal, comprising administering to the mammal, to the wound, or to a site of the skin condition, an effective amount of a polypeptide comprising an isolated or purified polypeptide according to claim 1.

45. A method according to claim 43, wherein the skin condition is selected from the group consisting of oxidative damage, damage, damage induced by sunlight exposure, ultraviolet radiation induced damage, skin aging and/or skin wrinkling.

46-48. (canceled)

49. A method according to claim 45, wherein the ultraviolet radiation induced damage is UVB induced damage or UVA induced damage.

50. A method according to claim 45, wherein the skin damage is HEV light induced damage and/or reduced expression of AQP-3.

51. (canceled)

52. A method according to claim 43, wherein the skin condition is characterised by CPD and/or 8-OHdG formation.

53. (canceled)

54. A method for inhibiting matrix metalloproteinase 1 (MMP1) expression and/or MMP1 activity in a cell, comprising treating the cell with an isolated or purified polypeptide according to claim 1.

55-56. (canceled)

57. A method for inhibiting 8-OHdG formation in a cell, comprising treating the cell with an isolated or purified polypeptide according to claim 1.

58. A method for inhibiting CPD formation in a cell, comprising treating the cell with an isolated or purified polypeptide according to claim 1.

59. (canceled)

60. A method for maintaining AQP3 expression and/or activity in a cell, comprising treating the cell with an isolated or purified polypeptide according to claim 1.

61. (canceled)

62. A method of increasing hydration or moisturisation of the skin of a subject, comprising administering to the skin an isolated or purified polypeptide according to claim 1.

* * * *